Formulation comprising Anti-CCR8 antibody, and use thereof

By adding appropriate buffers, stabilizers and surfactants to the anti-CCR8 antibody preparation, the problem of poor stability of the antibody in liquid solution is solved, and the high stability and biological activity of the preparation under different temperature conditions is achieved. in a variety of application environments.

WO2024240224A1PCT designated stage expired Publication Date: 2024-11-28ZAI LAB (SHANGHAI) CO LTD +1

Patent Information

Application Number
PCT/CN2024/094955
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-23
Filing Date
2024-05-23
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Existing anti-CCR8 antibody preparations are difficult to maintain stability in liquid solutions, and are prone to decomposition, aggregation or undesired chemical modifications, affecting their storage and transportation reliability.

Method used

Using liquid preparations containing anti-CCR8 antibodies, buffers, stabilizers and surfactants, the stability of the preparations under different temperature conditions is ensured by optimizing the combination of buffers, stabilizers and surfactants, including 5°C±3°C. , 25°C±2°C and 40°C±2°C, and solid antibody preparations were obtained by curing treatment.

Benefits of technology

The high stability of anti-CCR8 antibodies was achieved, and the purity and biological activity of the main components remained above 90% after storage. The preparation was also stable under oscillation and repeated freeze-thawing conditions, which significantly improved its application reliability in different environments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024094955-FTAPPB-I100001
    Figure PCTCN2024094955-FTAPPB-I100001
  • Figure PCTCN2024094955-FTAPPB-I100002
    Figure PCTCN2024094955-FTAPPB-I100002
  • Figure PCTCN2024094955-FTAPPB-I100003
    Figure PCTCN2024094955-FTAPPB-I100003
Patent Text Reader

Abstract

Provided is a liquid antibody formulation, comprising: (i) an anti-CCR8 antibody or an antigen-binding fragment; (ii) a buffer; (iii) a stabilizer; and (iv) a surfactant. Further provided is a method for treating cancer in a subject, comprising the step of administering to a subject the liquid antibody formulation or a delivery device (e.g., a pre-filled syringe) or drug comprising the liquid antibody formulation.
Need to check novelty before this filing date? Find Prior Art

Description

Preparations containing anti-CCR8 antibodies and uses thereof Technical Field

[0001] The present invention relates to the field of antibody preparations. More specifically, the present invention relates to pharmaceutical preparations comprising antibodies and / or antigen-binding fragments thereof that specifically bind to CCR8, and the therapeutic and / or preventive uses of the pharmaceutical preparations. Background Art

[0002] CCR8 (Chemokine receptor 8), a seven-transmembrane G-protein-coupled receptor, is a chemokine receptor that is highly expressed in tumor-infiltrating Treg cells and expressed at lower levels in Treg cells in the thymus, spleen, and peripheral blood. CCR8, through its interaction with its ligands, participates in the progression of various tumors and mediates tumor immunity. The specific high expression of CCR8 on Treg cells at tumor sites indicates that CCR8 is a very good biomarker for Treg cells at tumor sites and a highly promising target for tumor immunity.

[0003] Antibodies targeting human CCR8 can lead to Treg depletion in tumors and sensitize tumors to immune checkpoint therapies (such as anti-PD-1 therapy). Anti-CCR8 antibodies that specifically bind to CCR8 are described, for example, in PCT patent application PCT / CN2022 / 136276, the contents of which are incorporated herein by reference.

[0004] Antibody formulations not only need to be formulated in a manner suitable for administration to a subject, but also need to maintain their stability during storage and subsequent use, especially in liquid solutions where proteins tend to decompose, aggregate, denature, or undergo undesirable chemical modifications. Although some anti-CCR8 antibodies are known, there remains a need in the art for anti-CCR8 antibody formulations that are sufficiently stable for transport and storage while being suitable for administration.

[0005] SUMMARY OF THE INVENTION

[0006] The present invention satisfies the above needs by providing a stable pharmaceutical formulation containing an antibody that specifically binds to CCR8.

[0007] In one aspect, the present invention provides a liquid antibody formulation comprising (i) an anti-CCR8 antibody or an antigen-binding fragment thereof; (ii) a buffer, (iii) a stabilizer, and (iv) a surfactant.

[0008] In one embodiment, the anti-CCR8 antibody is any antibody that binds to a CCR8 molecule (e.g., a human CCR8 molecule), such as a polyclonal antibody, a monoclonal antibody, or a combination thereof. Preferably, in one embodiment, the anti-CCR8 antibody is a monoclonal antibody. In some embodiments, the anti-CCR8 antibody or its antigen-binding fragment reduces or prevents the binding of CCR8 to CCL1, and thereby, among other effects, inhibits the recruitment of regulatory T cells (Tregs) and / or the recruitment of signaling factors such as β-inhibitor proteins.

[0009] In one embodiment, the concentration of the anti-CCR8 antibody or antigen-binding fragment thereof in the liquid antibody formulation of the present invention is about 1-200 mg / mL. In another embodiment, the concentration of the anti-CCR8 antibody or antigen-binding fragment thereof in the liquid antibody formulation of the present invention is about 1 mg / mL to about 100 mg / mL. In other embodiments, the concentration of the anti-CCR8 antibody or antigen-binding fragment thereof in the liquid antibody formulation of the present invention is about 1, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 mg / mL.

[0010] In one embodiment, the buffer is selected from the group consisting of histidine-histidine hydrochloride buffer system, citric acid-sodium citrate buffer system, acetic acid-sodium acetate buffer system, and phosphate buffer system. Preferably, the buffer in the liquid antibody formulation is selected from the group consisting of histidine, histidine hydrochloride, and combinations thereof.

[0011] In one embodiment, the concentration of the buffer in the liquid antibody formulation of the present invention is about 0.1-100 mM. In one embodiment, the concentration of the buffer in the liquid antibody formulation of the present invention is about 1-50 mM, for example, about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 mM.

[0012] In one embodiment, the stabilizer is selected from sugars, polyols, amino acids and combinations thereof. Preferably, the stabilizer is selected from sucrose, trehalose, mannitol, arginine hydrochloride and combinations thereof.

[0013] In one embodiment, the concentration of the stabilizer in the liquid antibody formulation of the present invention is about 0.1-20% (w / v). In one embodiment, the concentration of the stabilizer in the liquid antibody formulation of the present invention is about 1-10% (w / v), for example, about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10%. In one embodiment, the stabilizer is about 0.1-20% (w / v) of a stabilizer selected from sugars and polyol stabilizers and amino acid stabilizers and combinations thereof.

[0014] In one embodiment, the surfactant is a nonionic surfactant. In one embodiment, the surfactant is, for example, selected from polysorbate surfactants, such as polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80, poloxamer, polyethylene glycol, or a combination thereof. In one embodiment, the surfactant is polysorbate 80.

[0015] In one embodiment, the concentration of the surfactant in the liquid antibody formulation of the present invention is about 0.001-0.5% (w / v). In one embodiment, the concentration of the surfactant in the liquid antibody formulation of the present invention is about 0.01-0.1% (w / v), for example, about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09 or 0.1%.

[0016] In one embodiment, the pH of the liquid formulation is about 4 to 8. In one embodiment, the pH of the liquid formulation is, for example, about 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, or 8.

[0017] In one embodiment, the liquid antibody formulation of the present invention comprises an anti-CCR8 antibody or antigen-binding fragment, a buffer, a stabilizer, and a surfactant, wherein the buffer is selected from a histidine-histidine hydrochloride buffer system, a citric acid-sodium citrate buffer system, an acetic acid-sodium acetate buffer system, a phosphate buffer system, and a combination thereof; the stabilizer is selected from sucrose, trehalose, mannitol, arginine hydrochloride, and a combination thereof; and the surfactant is selected from a polysorbate surfactant such as polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80, poloxamer, polyethylene glycol, and a combination thereof.

[0018] Preferably, the pH of the antibody formulation is about 4-8, more preferably, about 5-7.

[0019] In a preferred embodiment, the liquid antibody formulation of the present invention comprises

[0020] (i) about 1-200 mg / mL of an anti-CCR8 antibody or antigen-binding fragment thereof;

[0021] (ii) about 0.1-100 mM of a buffer selected from the group consisting of a histidine-histidine hydrochloride buffer system, a citric acid-sodium citrate buffer system, an acetic acid-sodium acetate buffer system, a phosphate buffer system, and combinations thereof;

[0022] (iii) about 0.1-20% (w / v) of a stabilizer selected from sugars, polyols, amino acids, and combinations thereof;

[0023] (iv) about 0.001-0.5% (w / v) of a nonionic surfactant;

[0024] The pH of the liquid preparation is about 4-8.

[0025] In a preferred embodiment, the liquid antibody formulation of the present invention comprises

[0026] (i) about 1-200 mg / mL of an anti-CCR8 antibody or antigen-binding fragment thereof;

[0027] (ii) about 1-100 mM of a buffer selected from the group consisting of a histidine-histidine hydrochloride buffer system, a citric acid-sodium citrate buffer system, an acetic acid-sodium acetate buffer system, a phosphate buffer system, and combinations thereof;

[0028] (iii) about 0.1-20% (w / v) of a stabilizer selected from the group consisting of sucrose, trehalose, mannitol, arginine hydrochloride, and combinations thereof;

[0029] (iv) about 0.01-0.5% (w / v) of a surfactant selected from the group consisting of a polysorbate surfactant such as polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80, a poloxamer, polyethylene glycol, and combinations thereof;

[0030] The pH of the liquid preparation is about 5-7.

[0031] In a preferred embodiment, the liquid antibody formulation of the present invention comprises

[0032] (i) about 1-100 mg / mL of an anti-CCR8 antibody or antigen-binding fragment thereof;

[0033] (ii) about 1-50 mM of a buffer selected from the group consisting of a histidine-histidine hydrochloride buffer system, a citric acid-sodium citrate buffer system, an acetic acid-sodium acetate buffer system, a phosphate buffer system, and combinations thereof;

[0034] (iii) about 1-10% (w / v) of a stabilizer selected from the group consisting of sucrose, trehalose, mannitol, arginine hydrochloride, and combinations thereof;

[0035] (iv) about 0.01-0.1% (w / v) of a surfactant selected from the group consisting of a polysorbate surfactant such as polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80, a poloxamer, polyethylene glycol, and combinations thereof;

[0036] The pH of the liquid preparation is about 5-7.

[0037] In a preferred embodiment, the liquid antibody formulation of the present invention comprises

[0038] (i) about 1-100 mg / mL of an anti-CCR8 antibody or antigen-binding fragment thereof;

[0039] (ii) about 1-50 mM of a buffer selected from the group consisting of a histidine-histidine hydrochloride buffer system, a citric acid-sodium citrate buffer system, an acetic acid-sodium acetate buffer system, a phosphate buffer system, and combinations thereof;

[0040] (iii) about 0.1-20% (w / v) selected from sucrose, trehalose, mannitol, arginine hydrochloride, and combinations thereof, and

[0041] (iv) about 0.01-0.1% (w / v) of a nonionic surfactant, for example, selected from polysorbate surfactants such as polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80, poloxamers, polyethylene glycol, and combinations thereof;

[0042] The pH of the liquid preparation is about 4.5-7.5.

[0043] In a preferred embodiment, the liquid antibody formulation of the present invention comprises about 1-200 mg / ml of an anti-CCR8 antibody or antigen-binding fragment, about 1-100 mM histidine-histidine hydrochloride buffer system, about 0.1%-20% sucrose, about 0.01-0.5% polysorbate 80, and a pH of about 5-7.

[0044] In a preferred embodiment, the liquid antibody formulation of the present invention comprises about 1-100 mg / ml of an anti-CCR8 antibody or antigen-binding fragment, about 1-50 mM histidine-histidine hydrochloride buffer system, about 1%-10% sucrose, about 0.01-0.1% polysorbate 80, and a pH of about 5-7.

[0045] In a preferred embodiment, the liquid antibody formulation of the present invention comprises about 10-50 mg / ml of an anti-CCR8 antibody or antigen-binding fragment, about 1-50 mM histidine-histidine hydrochloride buffer system, about 1%-10% sucrose, about 0.01-0.1% polysorbate 80, and a pH of about 5-7.

[0046] In a preferred embodiment, the liquid antibody formulation of the present invention comprises about 10-50 mg / ml of an anti-CCR8 antibody or antigen-binding fragment, about 20 mM histidine-histidine hydrochloride buffer system, about 7% sucrose, about 0.02-0.06% polysorbate 80, and a pH of about 5-7.

[0047] In a preferred embodiment, the liquid antibody formulation of the present invention comprises about 50 mg / ml anti-CCR8 antibody or antigen-binding fragment, about 20 mM histidine-histidine hydrochloride buffer system, about 7% sucrose, about 0.02-0.06% polysorbate 80, and a pH of about 5-7.

[0048] In a preferred embodiment, the liquid antibody formulation of the present invention comprises about 50 mg / ml anti-CCR8 antibody or antigen-binding fragment, about 20 mM histidine-histidine hydrochloride buffer system, about 7% sucrose, about 0.04% polysorbate 80, and a pH of about 6.

[0049] In one embodiment, the anti-CCR8 antibody or antigen-binding fragment thereof in the liquid formulation of the present invention can bind to CCR8 with high affinity, for example, with a binding affinity of 10 -7 M or less, preferably 10 -8 M to 10 -12 M's K D Specifically binds to CCR8.

[0050] In a preferred embodiment, the anti-CCR8 antibody or antigen-binding fragment thereof in the liquid preparation of the present invention

[0051] The anti-CCR8 antibody or antigen-binding fragment comprises a heavy chain variable region VH and / or a light chain variable region VL, wherein

[0052] (a) the VH comprises

[0053] (i) three complementarity determining regions (CDRs) selected from any one of the VHs represented by SEQ ID NOs: 1, 3, 4, 5, 6, 7, 11, 12, 26, 28, 30, 32, 34, 36, 37, 39, 41, 54-59, 61, and 66-70,

[0054] (ii) a combination of a HCDR1 of an amino acid sequence selected from SEQ ID NOs: 13, 71, 83, 115, and 117, a HCDR2 of an amino acid sequence selected from SEQ ID NOs: 14, 72, 77, 84, 89, 91, 92, 97, 114, 116, and 118, and a HCDR3 of an amino acid sequence selected from SEQ ID NOs: 15, 19-22, 73, 78, 81, 85, 93, 98, 112, and 113; or

[0055] (iii) a sequence comprising at least one and no more than 5, 4, 3, 2 or 1 amino acid changes (preferably amino acid substitutions, preferably conservative substitutions) in each of the three CDRs relative to the sequence of (i) or (ii);

[0056] and / or

[0057] (b) the VL comprises

[0058] (i) three CDRs in any one VL selected from SEQ ID NO: 2, 8, 9, 10, 27, 29, 31, 33, 35, 38, 40, 42-53, 60, and 62-65,

[0059] (ii) a combination of a LCDR1 having an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 74, 79, 86, 90, 94, 99, and 102-109, a LCDR2 having an amino acid sequence selected from the group consisting of SEQ ID NOs: 17, 75, 80, 87, 95, 100, 110, and 111, and a LCDR3 having an amino acid sequence selected from the group consisting of SEQ ID NOs: 18, 23-25, 76, 82, 88, 96, and 101; or

[0060] (iii) a sequence comprising at least one and no more than 5, 4, 3, 2 or 1 amino acid changes (preferably amino acid substitutions, preferably conservative substitutions) in each of the three CDRs relative to the sequence of (i) or (ii).

[0061] In a preferred embodiment, the anti-CCR8 antibody or antigen-binding fragment thereof in the liquid preparation of the present invention comprises a heavy chain variable region VH and / or a light chain variable region VL, wherein:

[0062] (a) the heavy chain variable region, VH, comprises or consists of an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, or 100% identical, to an amino acid sequence selected from ID NOs: 1, 3, 4, 5, 6, 7, 11, 12, 26, 28, 30, 32, 34, 36, 37, 39, 41, 54-59, 61, and 66-70;

[0063] and / or

[0064] (b) the light chain variable region, VL, comprises or consists of an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, or 100% identical, to an amino acid sequence selected from SEQ ID NO: 2, 8, 9, 10, 27, 29, 31, 33, 35, 38, 40, 42-53, 60, and 62-65.

[0065] In a preferred embodiment, the anti-CCR8 antibody or antigen-binding fragment thereof in the liquid formulation of the present invention comprises an IgG1 framework. Preferably, the antibody or antigen-binding fragment comprises one or more mutations in the Fc region, wherein the one or more mutations include an S239D mutation, an I332E mutation, an L235V mutation, an F243L mutation, an R292P mutation, a Y300L mutation, a P396L mutation, or a combination thereof. Preferably, the one or more mutations enhance antibody-dependent cellular cytotoxicity (ADCC).

[0066] In a preferred embodiment, the liquid formulation of the present invention comprises about 1-200 mg / ml of an anti-CCR8 antibody or antigen-binding fragment, about 0.1-100 mM buffer, about 0.1-20% (w / v) of a sugar or polyol stabilizer or an amino acid stabilizer or a combination thereof, and about 0.01-0.5% (w / v) surfactant, and has a pH of about 4.0-8.0, wherein the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2, and the LCDR3 of the anti-CCR8 antibody or antigen-binding fragment correspond to SEQ ID NOs: 13, 14, 19, 16, 17, and 18, respectively.

[0067] In a preferred embodiment, the liquids of the present invention are stable after storage, for example after at least 12 or 24 months at about 5°C ± 3°C, after at least 1, 2, 3 or 6 months at about 25°C ± 2°C, or after 1 month at 40°C ± 2°C, preferably having one or more of the following characteristics:

[0068] (i) the main peak variation is less than 5% and / or the preparation has a purity greater than 95% as measured by SEC-HPLC;

[0069] (ii) the sum of the changes in the components of the protein in the formulation (the main component, the acidic component, and the basic component) relative to the initial value on storage day 0, as measured by the iCIEF method, does not exceed 40% and / or the change in the main component does not exceed 20%, for example, after storage at 40°C ± 2°C for 1 month, the sum of the changes does not exceed about 40% or the change in the main component does not exceed about 20%, or after storage at 25°C for 2 months, the sum of the changes does not exceed about 20% or the change in the main component does not exceed about 15%;

[0070] (iii) Subvisible / insoluble particles measured by MFI or light obscuration method, containing no more than 6,000 particles of 10 μm and larger per bottle, and no more than 600 particles of 25 μm and larger per bottle;

[0071] (iv) stable under shaking and / or freeze-thaw cycles;

[0072] (v) the percentage change in the light chain and heavy chain (LC+HC) peak area is less than 5%, or the percentage change in the main peak area is less than 5%, as measured by reduced CE-SDS or non-reduced CE-SDS for size isomers, and / or the preparation has a purity greater than 90%; and

[0073] (vi) The biological activity should be 70%-130% of the activity of the reference product.

[0074] In one aspect, the present invention provides a solid antibody formulation obtained by subjecting the liquid antibody formulation of the present invention to a solidification treatment. The solidification treatment is performed, for example, by crystallization, spray drying, or freeze drying. In a preferred embodiment, the solid antibody formulation is, for example, in the form of a lyophilized powder injection.

[0075] The solid antibody formulation can be reconstituted in an appropriate solvent before use to form a reconstituted formulation of the present invention. The reconstituted formulation is also a liquid antibody formulation of the present invention. In one embodiment, the appropriate solvent is selected from water for injection, an organic solvent for injection, including but not limited to oil for injection, ethanol, propylene glycol, etc., or a combination thereof.

[0076] In another aspect, the present invention provides a delivery device comprising the liquid antibody formulation or solid antibody formulation of the present invention as described in the various embodiments herein.

[0077] In one embodiment, the delivery device of the present invention is provided in the form of a pre-filled syringe containing the liquid antibody formulation or solid antibody formulation of the present invention as described in each embodiment of this specification, which is used for intravenous injection, subcutaneous injection or intramuscular injection, or is an infusion, for example, for intravenous infusion.

[0078] In one embodiment, the present invention relates to a method for delivering an anti-CCR8 antibody or antigen-binding fragment to a subject, such as a mammal, comprising the step of administering to the subject, such as a mammal, the liquid antibody formulation or solid antibody formulation of the present application as described in each embodiment of the specification using a delivery device.

[0079] The present invention further provides a method for targeting a subpopulation of tumor-infiltrating lymphocytes (TILs), such as regulatory T cells (Tregs), in a subject, comprising administering to the subject a liquid antibody formulation or solid antibody formulation of the present invention, or a delivery device (e.g., a prefilled syringe) or a drug comprising the liquid antibody formulation or solid antibody formulation.

[0080] The present invention further provides a use of a liquid antibody formulation or a solid antibody formulation of the present invention in preparing a delivery device or a medicament for targeting a tumor infiltrating lymphocyte (TIL) subpopulation, such as regulatory T cells (Tregs), in a subject.

[0081] The present invention further provides a method for treating cancer in a subject, comprising administering to the subject a liquid antibody formulation or solid antibody formulation of the present invention, or a delivery device (e.g., a prefilled syringe) or a medicament comprising the liquid antibody formulation or solid antibody formulation.

[0082] The present invention further provides use of the liquid antibody formulation or solid antibody formulation of the present invention in the preparation of a delivery device or a medicament for treating cancer in a subject.

[0083] The above cancers include, for example, colorectal cancer, breast cancer, ovarian cancer, lung cancer (such as non-small cell lung cancer), melanoma, liver cancer, kidney cancer, bladder cancer or pancreatic ductal adenocarcinoma. BRIEF DESCRIPTION OF THE DRAWINGS

[0084] The preferred embodiments of the present invention described in detail below will be better understood when read in conjunction with the following drawings. For the purpose of illustrating the present invention, the drawings show presently preferred embodiments. However, it should be understood that the present invention is not limited to the means of the embodiments shown in the drawings.

[0085] FIG1 exemplarily shows the SEC-HPLC main peak purity graph of the anti-CCR8 antibody preparations of different formulations of the present application in Example 2 after being stored at 5±3° C. for 4 weeks.

[0086] FIG2 exemplarily shows the SEC-HPLC main peak purity graph of the anti-CCR8 antibody preparations of Example 2 of the present application with different formulations after being stored at 25±2° C. for 4 weeks.

[0087] FIG3 exemplarily shows the SEC-HPLC main peak purity graph of the anti-CCR8 antibody preparations of different formulations of the present application in Example 2 after being stored at 40° C.±2° C. for 4 weeks.

[0088] FIG4 exemplarily shows the icIEF main peak purity graph of the anti-CCR8 antibody preparations of Example 2 of the present application with different formulations after being stored at 5±3° C. for 4 weeks.

[0089] FIG5 exemplarily shows the icIEF main peak purity graph of the anti-CCR8 antibody preparations of Example 2 of the present application with different formulations after being stored at 25° C.±2° C. for 4 weeks.

[0090] FIG6 exemplarily shows the icIEF main peak purity graph of the anti-CCR8 antibody preparations of Example 2 of the present application with different formulations after being stored at 40° C.±2° C. for 4 weeks.

[0091] FIG7 exemplarily shows the SEC-HPLC main peak purity graph of the anti-CCR8 antibody preparations of Example 3 of the present application with different formulations after being stored at 5±3° C. for 8 weeks.

[0092] FIG8 exemplarily shows the SEC-HPLC main peak purity graph of the anti-CCR8 antibody preparations of different formulations of the present application in Example 3 after being stored at 25±2° C. for 8 weeks.

[0093] FIG9 exemplarily shows the SEC-HPLC main peak purity graph of the anti-CCR8 antibody preparations of Example 3 of the present application with different formulations after being stored at 40±2° C. for 4 weeks.

[0094] FIG10 exemplarily shows the SEC-HPLC main peak purity graph of the anti-CCR8 antibody preparations of Example 3 of the present application with different formulations after repeated freeze-thaw.

[0095] FIG11 exemplarily shows the icIEF main peak purity graph of the anti-CCR8 antibody preparations of Example 3 of the present application with different formulations after being stored at 5±3° C. for 8 weeks.

[0096] FIG12 exemplarily shows the icIEF main peak purity graph of the anti-CCR8 antibody preparations of Example 3 of the present application with different formulations after being stored at 25±2° C. for 8 weeks.

[0097] FIG13 exemplarily shows the icIEF main peak purity graph of the anti-CCR8 antibody preparations of Example 3 of the present application with different formulations after being stored at 40±2° C. for 4 weeks.

[0098] FIG14 exemplarily shows the icIEF main peak purity graph of the anti-CCR8 antibody preparations of Example 3 of the present application with different formulations after repeated freeze-thaw cycles.

[0099] FIG15 exemplarily shows the SEC-HPLC main peak purity graph of the anti-CCR8 antibody preparations of Example 4 of the present application with different formulations after being stored at 5±3° C. for 12 weeks.

[0100] FIG16 exemplarily shows the SEC-HPLC main peak purity graph of the anti-CCR8 antibody preparations of Example 4 of the present application with different formulations after being stored at 25±2° C. for 12 weeks.

[0101] FIG17 exemplarily shows the SEC-HPLC main peak purity graph of the anti-CCR8 antibody preparations of Example 4 of the present application with different formulations after being stored at 40±2° C. for 4 weeks.

[0102] FIG18 exemplarily shows the icIEF main peak purity graph of the anti-CCR8 antibody preparations of Example 4 of the present application with different formulations after being stored at 5±3° C. for 12 weeks.

[0103] FIG19 exemplarily shows the icIEF main peak purity graph of the anti-CCR8 antibody preparations of Example 4 of the present application with different formulations after being stored at 25±2° C. for 12 weeks.

[0104] FIG20 exemplarily shows the icIEF main peak purity graph of the anti-CCR8 antibody preparations of Example 4 of the present application with different formulations after being stored at 40±2° C. for 4 weeks.

[0105] Summary of the Invention

[0106] Although preferred embodiments of the present application have been shown and described herein, it will be apparent to one of ordinary skill in the art to which the invention pertains that such embodiments are provided by way of example only. Many variations, modifications, and substitutions will now occur to one of ordinary skill in the art to which the invention pertains without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. The following claims are intended to define the scope of the invention and are intended to cover thereby methods and structures within the scope of these claims and their equivalents.

[0107] For convenience, certain terms used in the specification, examples, and claims are collected here. Unless otherwise defined, all technical and scientific terms used in this disclosure have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0108] Where a range of values ​​is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit, is included, unless the context clearly dictates otherwise, in the upper and lower limits of the range and in any other stated or inclusive intervening values ​​within the stated range. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also inclusive, subject to any specifically excluded limits in the stated range. When the stated range includes one or both limits, ranges excluding either or both limits are also included. The terms "comprising" or "including" are meant to include the stated elements, integers or steps, but do not exclude any other elements, integers or steps.

[0109] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

[0110] When the word "about" immediately preceding a numerical value, it indicates a range of plus or minus 10% of that value, e.g., "about 50" indicates 45 to 55, "about 25,000" indicates 22,500 to 27,500, etc., unless the context of the disclosure indicates otherwise or is inconsistent with such interpretation. For example, in a list of numerical values ​​such as "about 49, about 50, about 55," "about 50" indicates a range that extends to less than half of the interval between the preceding and following values, e.g., greater than 49.5 and less than 52.5. In addition, the phrases "less than about" a value or "greater than about" a value should be understood according to the definition of the term "about" provided herein.

[0111] The compositions of the present disclosure can comprise, consist essentially of, or consist of the disclosed components.

[0112] All percentages, parts and ratios are based upon the total weight of the composition and all measurements made are at about 25°C, unless otherwise specified.

[0113] As used herein, the term "treating" is used herein, for example, with respect to a method of treating cancer, and generally includes administering a compound or composition to reduce the frequency of symptoms of a medical condition or delay its onset (e.g., cancer) relative to a subject that has not received the compound or composition. This can include reversing, reducing, or preventing the symptoms, clinical signs, and underlying pathology of the disease in a manner that improves or stabilizes the subject's disease (e.g., regression of tumor growth).

[0114] As used herein, the terms "subject," "individual," "host," and "patient" are used interchangeably herein to refer to a mammal, e.g., a primate, preferably a higher primate, such as a human (e.g., a patient having or at risk of having a disorder described herein).

[0115] The terms "cancer," "tumor," and "cancer" are used interchangeably herein and refer to cells that exhibit relatively autonomous growth, so they exhibit cell proliferation with an abnormal growth phenotype characterized by a significant loss of control. Typically, target cells for detection or treatment in the present application include precancerous (e.g., benign), malignant, pre-metastatic, metastatic, and non-metastatic cells. The term "normal," as used in the context of "normal cells," refers to cells of an untransformed phenotype or the morphology of untransformed cells that exhibit the type of tissue being examined. A "cancerous phenotype" generally refers to any of a variety of biological phenomena characteristic of cancer cells, which can vary with the type of cancer. A cancerous phenotype is typically identified by abnormalities in, for example, cell growth or proliferation (e.g., uncontrolled growth or proliferation), cell cycle regulation, cell mobility, cell-cell interactions, or metastasis.

[0116] I. Antibody Preparation

[0117] The term "antibody formulation" refers to a preparation that is in a form that permits the biological activity of the antibody as an active ingredient to be effective, and contains no additional components that are unacceptably toxic to a subject to which the formulation would be administered.

[0118] As used herein, the term "anti-CCR8 antibody preparation" refers to a combination of at least one anti-CCR8 antibody as an active ingredient and at least one inactive ingredient. After such combination, the anti-CCR8 antibody as the active ingredient is suitable for therapeutic or prophylactic administration to humans or non-human animals.

[0119] The antibody formulations of the present invention can be sterile, homogeneous, and / or isotonic. The antibody formulations can be directly prepared as aqueous liquid formulations, for example, ready-to-use pre-filled syringes, or prepared as lyophilized formulations and reconstituted (i.e., reconstituted) by dissolving and / or suspending in a physiologically acceptable solution immediately before use. In some embodiments, the anti-CCR8 antibody formulation is in the form of a liquid formulation, a lyophilized formulation, or a reconstituted formulation.

[0120] The term "lyophilization process" and the term "freeze-drying process" are used interchangeably herein and should be considered synonymous.

[0121] The term "lyophilized preparation" refers to a composition obtained or obtainable by freeze-drying a liquid preparation.

[0122] The term "reconstitution" refers to the process of dissolving and / or suspending a solid formulation (eg, a lyophilized formulation) in a physiologically acceptable solution to obtain a liquid formulation.

[0123] In specific embodiments, the anti-CCR8 antibody formulations of the present invention exhibit low to undetectable levels of antibody aggregation, degradation, or chemical modification during manufacturing, preparation, transportation, and long-term storage, resulting in minimal or no loss of biological activity of the anti-CCR8 antibody, and exhibiting high stability. Although the antibodies contained in the antibody formulations do not maintain 100% of their chemical structure after storage for a specific period of time, antibody formulations are generally considered "stable" if about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% of the antibody structure or function is maintained after storage for a specific period of time. In some embodiments, the anti-CCR8 antibody formulations of the present invention substantially retain their physical and chemical stability after storage.

[0124] Methods for monitoring protein stability are well known in the art. See, for example, Jones (1993) Adv. Drug Delivery Rev. 10:29-90; Lee, ed. (1991) Peptide and Protein Drug Delivery (Marcel Dekker, Inc., New York, NY); and the stability tests described below.

[0125] Because aggregation of antibodies in formulations can potentially lead to an increased immune response in patients, thereby causing safety concerns, there is a need to minimize or prevent aggregation of antibodies in formulations.

[0126] After a prolonged period of storage, a pharmaceutical composition is considered to have retained its physical stability at a given time point if it shows no visible signs of precipitation, aggregation, and / or denaturation (i.e., discoloration or loss of transparency) or measurable signs (e.g., by size exclusion chromatography (SEC) or UV light scattering). With respect to chemical stability, a protein, such as an antibody, is considered to have retained its chemical stability at a given time point when formulated into a pharmaceutical composition if measurements of chemical stability indicate that the protein (i.e., antibody) retains the biological activity of interest in the pharmaceutical composition. Methods for monitoring changes in chemical stability are well known in the art and include, but are not limited to, methods for detecting chemically altered forms of proteins using, for example, SDS-PAGE, SEC, and / or matrix-assisted laser desorption ionization / time-of-flight mass spectrometry; and methods related to changes in molecular charge using, for example, whole-column imaging capillary isoelectric focusing (iCIEF).

[0127] In one embodiment, the stability of the preparation is measured by measuring the percentage of the non-aggregating and non-decomposed antibody in the preparation at a selected temperature within a specific time period, wherein the higher the percentage of the non-aggregating and non-decomposed antibody in the preparation, the higher the stability of the preparation. The percentage of the non-aggregating and non-decomposed antibody can be measured by size exclusion chromatography (e.g., size exclusion high performance liquid chromatography).

[0128] As used herein, the phrase "acceptable degree of stability" means that at least about 92% of the anti-CCR8 antibody in the formulation is detected to be non-aggregated and non-degraded after storage at a specific temperature for a specific period of time. In some embodiments, an acceptable degree of stability means at least about 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the anti-CCR8 antibody is non-aggregated and non-degraded after storage at a specific temperature for at least 2 weeks, at least 28 days, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 18 months, at least 24 months, or more. When evaluating stability, the specific temperature at which the pharmaceutical formulation is stored can be any temperature between about -80°C and about 45°C, for example, at about -80°C, about -30°C, about -20°C, about 0°C, about 4°C-8°C, about 5°C, about 25°C, about 35°C, about 37°C, about 40°C, about 42°C, or about 45°C.

[0129] In some embodiments, the stable anti-CCR8 antibody formulations of the invention are administered parenterally to a subject. As used herein, the term "parenteral administration" includes, but is not limited to, subcutaneous, intradermal, intravascular (e.g., intravenous), intramuscular, spinal, intracranial, intrathecal, and intraperitoneal injections, as well as any similar injection or infusion techniques.

[0130] In a specific embodiment, the anti-CCR8 antibody formulation of the present invention is administered subcutaneously to a subject. The dosage and frequency of administration are determined based on age, sex, patient condition, other medications taken concurrently, adverse reactions, and other factors considered by the clinician.

[0131] In some embodiments, the stable liquid antibody formulation of the present invention comprises: (i) an anti-CCR8 antibody or an antigen-binding fragment thereof; (ii) a buffer; (iii) a stabilizer, and (iv) a surfactant, wherein the pH of the anti-CCR8 antibody formulation is about 4.0-8.0.

[0132] The antibody preparation of the present invention may comprise an anti-CCR8 antibody or antigen-binding fragment thereof that specifically binds to the CCR8 molecule. As used herein, the term "CCR8" is known to be a seven-transmembrane G protein-coupled receptor, belonging to the chemokine receptor protein class. Anti-CCR8 antibodies targeting CCR8 are disclosed in the prior art, for example, CN113260381A. The entire text of this document is incorporated herein by reference.

[0133] The terms "anti-CCR8 antibody," "anti-CCR8," "CCR8 antibody," or "antibody that binds to CCR8" refer to an antibody that is capable of binding to the CCR8 molecule with sufficient affinity so that the antibody can be used as a therapeutic and / or prophylactic agent targeting the CCR8 molecule. The binding of an antibody or antigen-binding fragment to CCR8 can be characterized or expressed by any method known in the art. For example, binding can be characterized by binding affinity, which can be the strength of the interaction between the antibody or antigen-binding fragment and the antigen. Binding affinity can be determined by any method known in the art, such as an in vitro binding assay. For example, the binding affinity of an antibody or antigen-binding fragment disclosed herein can be determined when assayed in an in vitro binding assay using cells expressing CCR8. In some embodiments, the equilibrium dissociation constant (K) of an anti-CCR8 antibody is D )≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM. In some embodiments, the anti-CCR8 antibody can bind with high affinity, for example, with 10 -7 M or less, preferably 10 -8 M to 10 -12 M's K D Specifically binds to CCR8. As used herein, when referring to an "anti-CCR8 antibody," antigen-binding fragments of the anti-CCR8 antibody are also included.

[0134] Typically, an antibody consists of an antigen-binding site (Fab) and a crystallizable fragment (Fc). Fab can bind to a specific antigen, thereby determining the specificity and affinity of the antibody. The Fc region is composed of two heavy chains and is used to regulate the activity of immune cells. Depending on the type of antibody, each heavy chain in this region is composed of two or three constant domains. The Fc segment can bind to Fc receptors (FcγRI, FcγRII, FcγRIII) expressed on the surface of immune cells, complement (C1q) and FcRn in the blood, thereby activating immune effects to eliminate foreign substances. The Fc segment determines the effector function of the antibody, including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

[0135] The term "complementarity determining region" or "CDR region" or "CDR" refers to those parts of the antibody heavy chain or light chain variable region that are arranged side by side in three-dimensional space to form an antigen binding surface. CDR is primarily responsible for binding to the antigen epitope. The CDRs of the heavy and light chains are generally referred to as CDR1, CDR2, and CDR3, and are numbered sequentially starting from the N-terminus. The CDRs located within the antibody heavy chain variable domain are referred to as HCDR1, HCDR2, and HCDR3, while the CDRs located within the antibody light chain variable domain are referred to as LCDR1, LCDR2, and LCDR3, which are located between relatively conserved framework regions (FRs). Generally speaking, from N-terminus to C-terminus, both the light and heavy chain variable domains comprise FR-1 (or FR1), CDR-1 (or CDR1), FR-2 (FR2), CDR-2 (CDR2), FR-3 (or FR3), CDR-3 (CDR3), and FR-4 (or FR4). The positions of the CDRs and framework regions can be determined using various definitions well known in the art, such as those of Kabat, Chothia, and AbM (see, e.g., Johnson et al., Nucleic Acids Res., 29:205-206 (2001); Chothia and Lesk, J. Mol. Biol., 196:901-917 (1987); Chothia et al., Nature, 342:877-883 (1989); Al-Lazikani et al., J. Mol. Biol., 273:927-748 (1997)).

[0136] When referring to antibodies defined by specific CDR sequences defined herein, the scope of said antibodies also encompasses antibodies whose variable region sequences comprise said specific CDR sequences, but whose declared CDR boundaries differ from the specific CDR boundaries defined herein due to the application of a different scheme (e.g., a different assignment system rule or combination).

[0137] In the context of the present invention, when referring to an amino acid sequence, the term "conservative substitution" means replacing the original amino acid with a new amino acid that does not substantially change the chemical, physical and / or functional properties of the antibody or fragment, such as its binding affinity to CCR8. In particular, common conservative substitutions of amino acids are well known in the art, such as substitutions of amino acid residues with similar side chains. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), β-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues of an anti-CCR8 antibody can be replaced with other amino acid residues from the same side chain family, and the altered antibody can be tested for function, particularly binding characteristics identical to the CCR8 molecule. Changes in the charge representation of the CDR surface are expected to affect the antibody's solvent interface; therefore, substitutions of non-conservative amino acid residues may have unpredictable effects on maintaining or improving the stability of the antibody in solution.

[0138] The term "antibody or antigen-binding fragment" includes, but is not limited to, polyclonal, monoclonal, monovalent, bispecific, multispecific, recombinant, heterologous, heterohybrid, human, humanized, chimeric, single-chain, nanobodies, and anti-idiotypic (anti-Id) antibodies, Fab fragments, Fab' fragments, F(ab')2 fragments, fragments produced by Fab expression libraries, Fd, Fv, disulfide-linked Fv (dsFv). Antibodies can be of any isotype / class (e.g., IgG, IgE, IgM, IgD, IgA, and IgY) or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2). The antigen-binding fragment refers to a molecule that is different from an intact antibody, comprises a portion of an intact antibody, and binds to the antigen to which the intact antibody binds.

[0139] A "humanized" antibody refers to a chimeric antibody comprising amino acid residues from complementary determining regions other than human and amino acid residues from the framework regions of a human antibody. In some embodiments, a humanized antibody will comprise substantially all of at least one, typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are regions of a human immunoglobulin sequence. A humanized antibody may also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin, such as human IgG1. Humanized antibodies can be used when administered to humans for therapeutic purposes, etc., because their antigenicity is reduced in humans. The term "specific binding" or similar terms means that the antibody or its antigen-binding fragment forms a relatively stable complex with the antigen under physiological conditions. Specific binding is characterized by at least about 1×10 -6 Equilibrium dissociation constants below M (e.g. K D The smaller the value, the tighter the binding). K D The value is preferably 1×10 -7 M or less, more preferably 1×10 -8 M or less, more preferably 1×10 -9 M to 10 -12 M. Methods for determining whether two molecules are specifically bound to each other are well known in the art, and examples thereof include competitive ELISA, surface plasmon resonance, and similar methods.

[0140] As used herein, the percent homology between two amino acid sequences is equal to the percent identity between the two sequences. The percent identity between two sequences is a function of the number of identical positions shared by the two sequences (i.e., % homology = number of identical positions / total number of positions × 100), taking into account the number of gaps, the length of each gap, which are introduced to perform an optimal comparison of the two sequences. Sequence alignment can be performed using various methods in the art to determine percent amino acid sequence identity, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or MEGALIGN (DNASTAR) software. Those skilled in the art can determine suitable parameters for measuring the comparison, including any algorithm required for obtaining maximum comparison over the full length of the compared sequences.

[0141] The amount of the antibody or antigen-binding fragment thereof contained in the antibody formulation of the present invention can vary depending on the specific intended use characteristics of the formulation, the specific environment, and the specific purpose for which the formulation is to be used. In some embodiments, the concentration of the anti-CCR8 antibody or antigen-binding fragment in the liquid formulation is from about 1 to about 200 mg / mL, preferably from about 1 to 100 mg / mL, for example, about 1, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 mg / mL.

[0142] In addition, the anti-CCR8 antibody formulations of the invention described herein are stable. In one embodiment, after storage at about -80°C, -30°C, -20°C, 5°C, 25°C, 37°C, 40°C, or 45°C for 6 months, the anti-CCR8 antibody in the antibody formulation of the invention is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% pure or greater, as determined by size exclusion chromatography. In one embodiment, after storage at about -80°C, -30°C, -20°C, 5°C, 25°C, 37°C, 40°C, or 45°C for 6 months, at least 50% of the anti-CCR8 antibody in the antibody formulation of the invention is in the non-basic and non-acidic form (i.e., the main peak or predominantly charged form), as determined by iCIEF.

[0143] In one embodiment, the anti-CCR8 antibody or antigen-binding fragment described herein comprises a light chain and / or a heavy chain that specifically binds to CCR8 and / or blocks the binding of CCL1 to CCR8. In another embodiment, the anti-CCR8 antibody or antigen-binding fragment described herein comprises a light chain and / or a heavy chain, and a crystallizable fragment (Fc) region operably linked to the antibody or antigen-binding fragment, wherein the antibody or antigen-binding fragment specifically binds to CCR8 and / or blocks the binding of CCL1 to CCR8.

[0144] In another embodiment, the present application provides a liquid antibody formulation comprising an anti-CCR8 antibody or antigen-binding fragment, wherein the anti-CCR8 antibody or antigen-binding fragment comprises a light chain and / or a heavy chain, and a crystallizable fragment (Fc) region comprising a mutation in at least one amino acid position operably linked to the antibody or antigen-binding fragment, wherein the antibody or antigen-binding fragment specifically binds to CCR8 and / or blocks the binding of CCL1 to CCR8, and wherein the mutation in the Fc region enhances antibody-dependent cellular cytotoxicity (ADCC).

[0145] In some embodiments, the crystallizable fragment (Fc) region comprises at least a portion of a human immunoglobulin constant region (Fc) with or without any mutations, wherein the mutation comprises an S239D mutation, an I332E mutation, an L235V mutation, an F243L mutation, an R292P mutation, a Y300L mutation, a P396L mutation, or a combination thereof.

[0146] In certain embodiments, the antibody of the present application is an IgG1, IgG2, IgG3 or IgG4 isotype. In a more specific embodiment, the antibody of the present application comprises the Fc domain of wild-type human IgG1. In another embodiment, the antibody of the present application comprises at least a portion of the Fc domain of human IgG1 having S239D / I332E mutation or L235V / F243L / R292P / Y300L / P396L mutation (according to the EU numbering system).

[0147] In some embodiments, the crystallizable fragment (Fc) region comprises at least a portion of human IgG1 Fc (wild type, SEQ ID NO: 119), or human IgG1 Fc including S239D / I332E mutations (SEQ ID NO: 121), or human IgG1 Fc including L235V / F243L / R292P / Y300L / P396L mutations (SEQ ID NO: 120), wherein the mutations enhance antibody-dependent cellular cytotoxicity (ADCC), thereby potentially better promoting the depletion of Tregs.

[0148] In some embodiments, the fragment crystallizable (Fc) region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 119-121:

[0149] SEQ ID NO:119

[0150] SEQ ID NO:120

[0151] SEQ ID NO:121

[0152] In any embodiment disclosed herein, the antibody or antigen-binding fragment comprises a light chain CDR (LCDR or LCDR1-3). The light chain CDR can be the complementarity determining region of the light chain of the antibody or antigen-binding fragment. The light chain CDR may comprise a continuous sequence of amino acid residues, or two or more continuous sequences of amino acid residues, which are separated by non-complementarity determining regions such as framework regions and are optionally located on its flanks. In some instances, the light chain CDR comprises two or more light chain CDRs, which may be referred to as LCDR1, LCDR2, etc. In advantageous instances, the light chain CDR comprises three light chain CDRs, which may be referred to as LCDR1, LCDR2, and LCDR3, respectively. In some instances, a group of CDRs present on a common light chain may be collectively referred to as LCDR.

[0153] In other embodiments, the antibody or antigen-binding fragment comprises a heavy chain CDR (HCDR or HCDR1-3). The heavy chain CDR can be the complementarity determining region of the heavy chain of the antibody or antigen-binding fragment. The heavy chain CDR may comprise a continuous sequence of amino acid residues, or two or more continuous sequences of amino acid residues, which are separated by non-complementarity determining regions such as framework regions and are optionally located on its flanks. In some instances, the heavy chain CDR comprises two or more heavy chain CDRs, which may be referred to as HCDR1, HCDR2, etc. In advantageous instances, the heavy chain CDR comprises three heavy chain CDRs, which may be referred to as HCDR1, HCDR2, and HCDR3, respectively. In some instances, a group of CDRs present on a common heavy chain may be collectively referred to as HCDRs.

[0154] In other embodiments, the antibody or antigen-binding fragment specifically binds to CCR8. As used herein, CCR8 may also refer to an ortholog, homolog, codon-optimized form, truncated form, fragmented form, mutant form, or any other known derivative form of the CCR8 sequence. For example, CCR8 may be human CCR8, mouse CCR8, or cynomolgus monkey CCR8.

[0155] Binding specificity can be determined by complementary determining regions or CDRs, such as light chain CDRs or heavy chain CDRs. In many cases, binding specificity is determined by light chain CDRs and heavy chain CDRs. Compared to other reference antigens, a given combination of heavy chain CDRs and light chain CDRs provides a given binding pocket that imparts greater affinity and / or specificity to CCR8. In some embodiments, the antibody or antigen-binding fragment reduces or even prevents the binding of CCR8 to CCL1, and thus, among other effects, inhibits the recruitment of regulatory T cells and / or the recruitment of signaling factors such as β-inhibitor proteins.

[0156] In embodiments, the antibody or antigen-binding fragment may comprise any of the sequences listed in Table 1. Additionally or alternatively, the antibody or antigen-binding fragment may comprise a sequence that is at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of the sequences listed in Tables 1-3, including any ranges having such values ​​as endpoints (e.g., 60%-85%).

[0157] In some embodiments, the antibody or antigen-binding fragment comprises vH and vL, or any combination of LCDRs and HCDRs selected from the following.

[0158] Table 1. Variable region amino acid sequences and CDRs using the Kabat nomenclature system

[0159] Table 2. Amino acid sequences of variable regions

[0160] Table 3. CDR amino acid sequences of Kabat nomenclature system

[0161] Exemplary anti-CCR8 antibodies that can be included in the antibody formulations of the present invention are, for example, novel anti-CCR8 antibodies that specifically bind to CCR8 as described in PCT patent application PCT / CN2022 / 136276, Hu149-1, Hu149-2, Hu149-3, Hu149-4, Hu149-5, Hu149-6, Hu149-7, Hu149-8, Hu149-9, 11-24, Hu149- ... -11G1, Hu149-11G1m, Hu149-11G1x, Hu149-12G1m, Hu149-12G1x, Hu348-1, Hu348-2, Hu348-3, Hu348-4, Hu348-5, Hu348-6, Hu348-7, Hu348-8, Hu348-9, Hu348-4-m2G1, Hu348-4-m2G1m and Hu348-3 8-4-m2G1x, 191E12H8, 234G9C12, 273H2G6, 348E2D11, 149F2C10, 153D4G2, 160D1E3, 164G10D6 , 204A2G12, 262C2G7, 499B1A5, 149F2C10_N28Q, 149F2C10_N28I, 149F2C10_N28S, 149F2C10_G2 9A, 149F2C10_G29I, 149F2C10_G29I, 149F2C10_G29V, 499B1A5_L28(NtoS), 499B1A5_L28(Nto Y), 499B1A5_L29(GtoA), 499B1A5_L51(MtoA), 499B1A5_H100D(MtoA), 499B1A5_H100D(MtoF). The variable region sequence characteristics are summarized in Tables 1 to 3 above, and the constant region comprises wild-type human IgG1 Fc (SEQ ID NO: 119), or human IgG1 Fc comprising S239D / I332E mutations (SEQ ID NO: 121, indicated by a G1x suffix), or human IgG1 Fc comprising L235V / F243L / R292P / Y300L / P396L mutations (SEQ ID NO: 120, indicated by a G1m suffix).

[0162] As one embodiment, the anti-CCR8 antibody or antigen-binding fragment in the antibody preparation described in the present application comprises a heavy chain variable region VH and / or a light chain variable region VL, wherein

[0163] (a) the VH comprises

[0164] (i) three complementarity determining regions (CDRs) in any one of the VHs selected from SEQ ID NOs: 1, 3, 4, 5, 6, 7, 11, 12, 26, 28, 30, 32, 34, 36, 37, 39, 41, 54-59, 61, and 66-70,

[0165] (ii) a combination of a HCDR1 of an amino acid sequence selected from SEQ ID NOs: 13, 71, 83, 115, and 117, a HCDR2 of an amino acid sequence selected from SEQ ID NOs: 14, 72, 77, 84, 89, 91, 92, 97, 114, 116, and 118, and a HCDR3 of an amino acid sequence selected from SEQ ID NOs: 15, 19-22, 73, 78, 81, 85, 93, 98, 112, and 113; or

[0166] (iii) a sequence comprising at least one and no more than 5, 4, 3, 2 or 1 amino acid changes (preferably amino acid substitutions, preferably conservative substitutions) in each of the three CDRs relative to the sequence of (i) or (ii);

[0167] and / or

[0168] (b) the VL comprises

[0169] (i) three CDRs in any one VL selected from SEQ ID NO: 2, 8, 9, 10, 27, 29, 31, 33, 35, 38, 40, 42-53, 60, and 62-65,

[0170] (ii) a combination of a LCDR1 having an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 74, 79, 86, 90, 94, 99, and 102-109, a LCDR2 having an amino acid sequence selected from the group consisting of SEQ ID NOs: 17, 75, 80, 87, 95, 100, 110, and 111, and a LCDR3 having an amino acid sequence selected from the group consisting of SEQ ID NOs: 18, 23-25, 76, 82, 88, 96, and 101; or

[0171] (iii) a sequence comprising at least one and no more than 5, 4, 3, 2 or 1 amino acid changes (preferably amino acid substitutions, preferably conservative substitutions) in each of the three CDRs relative to the sequence of (i) or (ii).

[0172] As another embodiment, in the antibody formulation described herein, the HCDR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 13 and 115, the HCDR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 14, 89 and 114, and the HCDR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 15 and 19-22; the LCDR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 16, 90 and 102-106, the LCDR2 comprises a sequence selected from the group consisting of SEQ ID NO: 17, and the LCDR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 18 and 23-25.

[0173] As another embodiment, the HCDR1 comprises a sequence selected from SEQ ID NOs: 83 and 117, the HCDR2 comprises a sequence selected from SEQ ID NOs: 84, 116 and 118, and the HCDR3 comprises a sequence of SEQ ID NO: 85;

[0174] The LCDR1 comprises the sequence of SEQ ID NO:86, LCDR2 comprises the sequence of SEQ ID NO:87, and LCDR3 comprises the sequence of SEQ ID NO:88.

[0175] In another embodiment, the HCDR1, HCDR2 and HCDR3 in the antibody formulation of the present invention are an amino acid sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15; SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 19; SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 20; SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 21; SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 22; SEQ ID NO: 71, SEQ ID NO: 72 and SEQ ID NO: 73; SEQ ID NO: 71, SEQ ID NO: 77 and SEQ ID NO: 78; SEQ ID NO: 71, SEQ ID NO: 72 and SEQ ID NO: 81; SEQ ID NO: 83, SEQ ID NO: 84 and SEQ ID NO: 85; SEQ ID NO: 13, SEQ ID NO: 89 and SEQ ID NO: 15; SEQ ID NO: 16 NO:13, SEQ ID NO:91 and SEQ ID NO:15; SEQ ID NO:71, SEQ ID NO:92 and SEQ ID NO:93; SEQ ID NO:13, SEQ ID NO:97 and SEQ ID NO:98; SEQ ID NO:13, SEQ ID NO:97 and SEQ ID NO:112; SEQ ID NO:13, SEQ ID NO:97 and SEQ ID NO:113; SEQ ID NO:13, SEQ ID NO:114, and SEQ ID NO:15; SEQ ID NO:115, SEQ ID NO:114, and SEQ ID NO:15; SEQ ID NO:83, SEQ ID NO:116, and SEQ ID NO:85; SEQ ID NO:117, SEQ ID NO:116, and SEQ ID NO:85; and SEQ ID NO:83, SEQ ID NO:118 and SEQ ID NO:85;

[0176] The LCDR1, the LCDR2 and the LCDR3 are an amino acid sequence selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18; SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 23; SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 24; SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 25; SEQ ID NO: 74, SEQ ID NO: 75 and SEQ ID NO: 76; SEQ ID NO: 79, SEQ ID NO: 80 and SEQ ID NO: 76; SEQ ID NO: 79, SEQ ID NO: 75 and SEQ ID NO: 82; SEQ ID NO: 86, SEQ ID NO: 87 and SEQ ID NO: 88; SEQ ID NO: 90, SEQ ID NO: 17 and SEQ ID NO: 18; SEQ ID NO: 94, SEQ ID NO: 95 and SEQ ID NO: 96; SEQ ID NO: 79, SEQ ID NO: 80 and SEQ ID NO: 86; NO:75 and SEQ ID NO:76; SEQ ID NO:99, SEQ ID NO:100 and SEQ ID NO:101; SEQ ID NO:101, SEQ ID NO:17 and SEQ ID NO:18; SEQ ID NO:103, SEQ ID NO:17 and SEQ ID NO:18; SEQ ID NO:104, SEQ ID NO:17 and SEQ ID NO:18; SEQ ID NO:105, SEQ ID NO:17 and SEQ ID NO:18; SEQ ID NO:106, SEQ ID NO:17 and SEQ ID NO:18; SEQ ID NO:107, SEQ ID NO:100 and SEQ ID NO:101; SEQ ID NO:108, SEQ ID NO:100 and SEQ ID NO:101; SEQ ID NO:109, SEQ ID NO:100 and SEQ ID NO:101; and SEQ ID NO:99, SEQ ID NO:111 and SEQ ID NO:101.

[0177] In one embodiment, the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 in the antibody formulation of the present invention are an amino acid sequence selected from the group consisting of SEQ ID NOs: 13, 14, 15, 16, 17 and 18; SEQ ID NOs: 13, 14, 19, 16, 17 and 18; SEQ ID NOs: 13, 14, 20, 16, 17 and 18; SEQ ID NOs: 13, 14, 21, 16, 17 and 18; SEQ ID NOs: 13, 14, 22, 16, 17 and 18; SEQ ID NOs: 13, 14, 15, 16, 17 and 23; SEQ ID NOs: 13, 14, 15, 16, 17 and 24; SEQ ID NOs: 13, 14, 15, 16, 17 and 25; SEQ ID NOs: 13, 14, 19, 16, 17 and 23; SEQ ID NO: 13, 14, 20, 16, 17 and 23; SEQ ID NO: 13, 14, 21, 16, 17 and 23; SEQ ID NO: 13, 14, 22, 16, 17 and 23; SEQ ID NO: 13, 89, 15, 90, 17 and 18; SEQ ID NO: 13, 89, 15, 102, 17 and 18; SEQ ID NO: 13, 89, 15, 103, 17 and 18; SEQ ID NO: 13, 89, 15, 104, 17 and 18; SEQ ID NO: 13, 89, 15, 16, 17 and 18; SEQ ID NO: 13, 89, 15, 105, 17 and 18; SEQ ID NO: 13, 89, 15, 106, 17 and 18; SEQ ID NO:13, 114, 15, 16, 17 and 18; and SEQ ID NO:115, 114, 15, 16, 17 and 18.

[0178] In one embodiment, the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 in the antibody formulation of the present invention are an amino acid sequence selected from the group consisting of SEQ ID NOs: 83, 84, 85, 86, 87 and 88; SEQ ID NOs: 83, 116, 85, 86, 87 and 88; SEQ ID NOs: 117, 116, 85, 86, 87 and 88; and SEQ ID NOs: 83, 118, 85, 86, 87 and 88.

[0179] In one embodiment, the anti-CCR8 antibody or antigen-binding fragment in the antibody preparation of the present invention comprises a heavy chain variable region VH and / or a light chain variable region VL, wherein:

[0180] (a) the heavy chain variable region, VH, comprises or consists of an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, or 100% identical, to an amino acid sequence selected from ID NOs: 1, 3, 4, 5, 6, 7, 11, 12, 26, 28, 30, 32, 34, 36, 37, 39, 41, 54-59, 61, and 66-70;

[0181] and / or

[0182] (b) the light chain variable region, VL, comprises or consists of an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, or 100% identical, to an amino acid sequence selected from SEQ ID NO: 2, 8, 9, 10, 27, 29, 31, 33, 35, 38, 40, 42-53, 60, and 62-65.

[0183] In one embodiment, the anti-CCR8 antibody or antigen-binding fragment in the antibody formulation of the present invention comprises a heavy chain variable region VH and a light chain variable region VL, wherein the heavy chain variable region VH and the light chain variable region VL respectively comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 and 2; SEQ ID NOs: 3 and 2; SEQ ID NOs: 4 and 2; SEQ ID NOs: 5 and 2; SEQ ID NOs: 6 and 2; SEQ ID NOs: 7 and 2; SEQ ID NOs: 1 and 8; SEQ ID NOs: 1 and 9; SEQ ID NOs: 1 and 10; SEQ ID NOs: 3 and 8; SEQ ID NOs: 4 and 8; SEQ ID NOs: 5 and 8; SEQ ID NOs: 6 and 8; SEQ ID NOs: 11 and 8; SEQ ID NOs: 12 and 8; SEQ ID NOs: 34 and 35; SEQ ID NOs: 34 and 43; SEQ ID NOs: 34 and 44; SEQ ID NOs: 34 and 45; SEQ ID NOs: 34 and 46; SEQ ID NOs: 34 and 47; SEQ ID NOs: 34 and 48; SEQ ID NOs: 34 and 49; SEQ ID NOs: 40 and 41; SEQ ID NOs: 41 and 42; SEQ ID NOs: 42 and 43; SEQ ID NOs: 43 and 44; SEQ ID NOs: 43 and 45; SEQ ID NOs: 43 and 46 NO:34 and 48; SEQ ID NO:56 and 2; SEQ ID NO:57 and 2; SEQ ID NO:58 and 2; SEQ ID NO:59 and 2; SEQ ID NO:56 and 60; SEQ ID NO:57 and 60; and SEQ ID NO:58 and 60; and SEQ ID NO:59 and 60.

[0184] In one embodiment, the heavy chain variable region VH and light chain variable region VL in the antibody preparation of the present invention respectively comprise an amino acid sequence selected from the following groups: SEQ ID NOs: 32 and 33; SEQ ID NOs: 61 and 62; SEQ ID NOs: 61 and 63; SEQ ID NOs: 61 and 64; SEQ ID NOs: 61 and 65; SEQ ID NOs: 66 and 62; SEQ ID NOs: 67 and 62; SEQ ID NOs: 68 and 62; SEQ ID NOs: 69 and 62; and SEQ ID NOs: 70 and 62.

[0185] In one embodiment, the antibody in the antibody formulation of the present invention can be selected from polyclonal antibodies, monoclonal antibodies, humanized antibodies, chimeric antibodies, monovalent antibodies, multivalent antibodies, bispecific antibodies, multispecific antibodies, and any combination thereof.

[0186] In one embodiment, the antigen-binding fragment in the antibody formulation of the present invention may be scFv, Fab', single-chain Fab (scFab'), Fd or F(ab')2, sFC or VHH.

[0187] (ii) Buffer and pH

[0188] Solution pH and buffer are among the most important parameters affecting the physicochemical stability of biopharmaceuticals. pH can regulate the charge distribution on the protein surface, thereby influencing the attractive and repulsive forces within and between biopharmaceutical molecules. It can also modulate the interaction between biopharmaceuticals and other small molecules, such as excipients. Therefore, pH is a key factor in formulation optimization. Different buffers can also affect protein stability.

[0189] In general, buffer or pH adjusting agent are used to keep an acceptable pH level in the liquid preparation, thereby keeping the stability of the antibody. Liquid preparation is usually adjusted to make the pH remain in the scope of about 4-8, about 4.5-7.5, about 5.0-6.5 or about 5.3-6.3. The scope between the above-mentioned pH also wishes to be a part of the present invention. For example, it is desirable to include the scope of the value of the upper and / or lower limit using the combination of the above-mentioned any value. In some embodiments, the pH value of the liquid preparation is for example about 4,4.5,5,5.5,6,6.5,7,7.5 or 8. In one embodiment, the pH value of the liquid preparation is for example about 5-7.

[0190] Suitable buffers for use in the present invention include, but are not limited to, histidine-histidine hydrochloride buffer systems, citric acid-sodium citrate buffer systems, acetic acid-sodium acetate buffer systems, and phosphate buffer systems. In one embodiment, the buffer in the liquid antibody formulation is selected from histidine, histidine hydrochloride, and combinations thereof.

[0191] In some embodiments, the concentration of the buffer included in the antibody formulation of the present invention is about 0.1-100 mM. In some embodiments, the concentration of the buffer included in the antibody formulation of the present invention is about 1-50 mM, for example, about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 mM.

[0192] (iii) Stabilizer

[0193] Suitable stabilizers for the present invention can be sugars, polyols and amino acids, and their protein protection mechanism is "preferential exclusion". Such excipients are preferentially excluded from the surface of the protein, increasing the chemical potential energy of the protein. Due to the increase in surface area after protein denaturation and unfolding, the interaction with the excipients increases, causing the chemical potential energy to increase, thereby making the activation energy required for the conformational denaturation of the protein greater, making the protein naturally resistant to sugars as stabilizers, including but not limited to monosaccharides such as fructose, maltose, galactose, glucose, D-mannose, sorbose, etc.; disaccharides such as lactose, sucrose, trehalose, cellobiose, etc.; polysaccharides such as raffinose, melezitose, maltodextrin, dextran, starch, etc.; and sugar alcohols such as mannitol, xylitol, maltitol, lactitol, xylitol sorbitol (glucitol), etc., and combinations thereof. For example, the sugar can be sucrose, trehalose, mannitol, or a combination thereof.

[0194] The stabilizer may also be an amino acid stabilizer, such as arginine hydrochloride.

[0195] (iv) Surfactants

[0196] The compositions of the present invention may optionally further comprise a pharmaceutically acceptable surfactant. As used herein, the term "surfactant" refers to a class of amphiphilic molecules having both hydrophilic and lipophilic groups that are capable of altering (generally reducing) the surface tension of a liquid or the interfacial tension between two phases. In certain embodiments, a "surfactant" may help improve the stability of any anti-CCR8 antibody formulation described herein by reducing the surface tension of a liquid or the interfacial tension between two phases. For example, a surfactant may reduce aggregation of the formulated antibody and / or minimize particle formation and / or reduce adsorption in the formulation. Surfactants may also improve the stability of the antibody during and after freeze / thaw cycles.

[0197] In a preferred embodiment, the surfactant in the liquid formulation of the present invention is a nonionic surfactant. Nonionic surfactants can inhibit protein aggregation, and the mechanism may be that the surfactant tends to be arranged at the air-liquid interface, thereby causing the protein to leave the interface and inhibit protein aggregation and denaturation.

[0198] Specific nonionic surfactants that can be included in the formulations of the present invention include, for example, polysorbates such as polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80, poloxamers, polyethylene glycol, pluronics, or combinations thereof. In one embodiment, polysorbate 80 is preferred.

[0199] The amount of nonionic surfactant contained in the antibody formulations of the present invention can vary with the specific purpose characteristics of the formulation, the specific environment, and the specific purpose of using the formulation. In certain embodiments, the formulation can contain a concentration of about 0.001-0.5% (w / v), preferably about 0.01-0.1% (w / v), for example, about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09 or 0.1% (w / v).

[0200] II Preparation and Detection Analysis

[0201] The liquid antibody preparation described in the present invention adopts recombinant DNA technology to efficiently express specific anti-CCR8 antibodies or antigen-binding fragments thereof in the mammalian cell expression system CHO. After cell culture, harvesting, virus inactivation, and high-level purification, specific excipients are added and the preparation is prepared through common preparation processes in the field such as sterilization filtration, filling, stoppering, capping and visual inspection.

[0202] In some embodiments, the present invention obtains a solid antibody formulation by solidifying the liquid antibody formulation, wherein the solidification is performed by, for example, crystallization, spray drying, or freeze drying. The solid antibody formulation is, for example, in the form of a lyophilized powder injection.

[0203] The stability of the purified antibody composition produced by the process during storage is related to the product's quality attributes. For example, antibody aggregation, degradation, or chemical modification can lead to antibody heterogeneity, including size and charge heterogeneity, thereby affecting the quality of the antibody drug product. Therefore, it is necessary to monitor the stability of the purified antibody composition produced by the process.

[0204] Various methods are known in the art for detecting the stability of antibody compositions. Product stability testing indicators can include appearance, visible foreign matter, protein content, turbidity, purity (SEC-HPLC method, non-reduced CE-SDS method) and charge variants (iCIEF method, CEX-HPLC method, etc.). In addition, the efficacy or biological activity of the antibody can be tested. For example, the binding ability of the antibody in the formulation to its antigen CCR8 can be tested. A variety of methods are known to those skilled in the art for quantitatively determining the specific binding of the antibody to the antigen, such as immunoassays, ELISA, etc.

[0205] Stability studies generally include long-term stability studies under actual storage conditions, accelerated stability studies, and forced condition test studies. Under accelerated and forced conditions, degradation is accelerated, and degradation products can be monitored at an earlier time point and in larger amounts. Therefore, accelerated and forced condition tests can be used to clarify the degradation pathway of the target antibody product, which helps to understand the nature (mechanism) of the degradation of the target antibody product; and provide the stability of the product under deviation from the optimal storage conditions and extreme conditions. In one embodiment of the present invention, the antibody composition sample is placed at an elevated temperature, such as about 40°C ± 2°C, 25°C ± 2°C, for forced or accelerated stability studies. In addition, an oscillation experiment or a repeated freeze-thaw experiment can be performed to detect the stability properties of the product. For example, an oscillation experiment is performed at 650r / min in the dark at room temperature for 1-5 days. For example, the product can be frozen below -30°C for one day and then thawed at room temperature or in a water bath at 25°C as a freeze-thaw cycle, and a repeated freeze-thaw experiment is performed, in which 1-6 repeated freeze-thaw cycles can be implemented.

[0206] As a preferred embodiment, the antibody formulations according to the present invention as described herein in the various embodiments are stable after storage, for example, at about 5°C ± 3°C for at least 12 or 24 months, at about 25°C ± 2°C for at least 1, 2, or 3 or 6 months, or at 40°C ± 2°C for 1 month, preferably having one or more of the following characteristics:

[0207] (i) the main peak variation is less than 5% and / or the preparation has a purity greater than 95% as measured by SEC-HPLC;

[0208] (ii) the sum of the changes in the components of the protein in the formulation (the main component, the acidic component, and the basic component) relative to the initial value on storage day 0, as measured by the iCIEF method, does not exceed 40% and / or the change in the main component does not exceed 20%, for example, after storage at 40°C ± 2°C for 1 month, the sum of the changes does not exceed about 40% or the change in the main component does not exceed about 20%, or after storage at 25°C for 2 months, the sum of the changes does not exceed about 20% or the change in the main component does not exceed about 15%;

[0209] (iii) Subvisible / insoluble particles measured by MFI or light obscuration method, containing no more than 6,000 particles of 10 μm and larger per bottle, and no more than 600 particles of 25 μm and larger per bottle;

[0210] (iv) stable under shaking and / or freeze-thaw cycles;

[0211] (v) the percentage change in the light chain and heavy chain (LC+HC) peak area is less than 5%, or the percentage change in the main peak area is less than 5%, as measured by reduced CE-SDS or non-reduced CE-SDS for size isomers, and / or the preparation has a purity greater than 90%; and

[0212] (vi) The biological activity should be 70%-130% of the activity of the reference product.

[0213] More preferably, the formulation is stable under shaking and / or repeated freeze-thaw cycles.

[0214] III. Application

[0215] The antibody preparations of the present invention comprising anti-CCR8 antibodies can be used to treat, improve or prevent cancer-related diseases. Cancer can be a blood cancer or a solid tumor. Blood cancers include, but are not limited to, leukemia, lymphoma (e.g., non-Hodgkin's lymphoma) and myeloma. Solid tumors include, but are not limited to, colorectal cancer (CRC), spleen cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, melanoma, bile duct cancer, gallbladder cancer, thyroid cancer, sarcoma, kidney cancer, bladder cancer, uterine corpus cancer, ovarian cancer, lung cancer, prostate cancer, head and neck cancer, thymus cancer, liver cancer, testicular cancer, urothelial cancer, esophageal cancer and gastric cancer.

[0216] In some embodiments, the antibody preparations of the invention are used to treat, ameliorate or prevent colorectal cancer, breast cancer, ovarian cancer, lung cancer (eg, non-small cell lung cancer), melanoma, liver cancer, kidney cancer, bladder cancer or pancreatic ductal adenocarcinoma.

[0217] In some embodiments, a liquid antibody formulation or solid antibody formulation of the invention is administered to an individual in need thereof in combination with one or more other agents, such as a therapeutic antibody, such as an anti-PD-1 antibody.

[0218] The present invention also provides a formulation of the invention as described herein in various embodiments for use as a medicament, for example, for delivering an anti-CCR8 antibody to a mammal, or for treating, preventing or ameliorating one or more of the above-mentioned diseases and conditions. Preferably, the mammal is a human.

[0219] The antibody formulations of the present invention can be administered to a subject or patient. Administration is typically by infusion or by syringe. Therefore, the present invention provides a delivery device (e.g., a syringe) comprising an antibody formulation of the present invention (e.g., a prefilled syringe).

[0220] The present invention also provides a pre-filled syringe comprising the antibody formulation of the present invention, preferably for intravenous, subcutaneous or intramuscular injection, or an infusion, such as for intravenous infusion.

[0221] In some embodiments, the liquid antibody formulation or solid antibody formulation of the invention is used to prepare a delivery device or pre-filled syringe or medicament for targeting a tumor infiltrating lymphocyte (TIL) subpopulation, such as regulatory T cells (Tregs), in a subject.

[0222] In some embodiments, the anti-CCR8 antibody or antigen-binding fragment in the antibody formulation of the present invention inhibits Tregs migration and / or eliminates Tregs through antibody-dependent cellular cytotoxicity (ADCC).

[0223] In some embodiments, the liquid antibody formulation or solid antibody formulation of the invention is used to prepare a delivery device or prefilled syringe or medicament for treating cancer in a subject, e.g., colorectal cancer, breast cancer, ovarian cancer, lung cancer (e.g., non-small cell lung cancer), melanoma, liver cancer, kidney cancer, bladder cancer, or pancreatic ductal adenocarcinoma.

[0224] The following examples are described to assist understanding of the present invention. The examples are not intended to, and should not be interpreted in any way as, limiting the scope of protection of the present invention. Example

[0225] Materials and methods

[0226] 1.1. Information on auxiliary materials and packaging materials

[0227] Information on excipients and packaging materials used in the study is shown in Table 4.

[0228] Table 4 Information on auxiliary materials and packaging materials

[0229] 1.2. Instruments used

[0230] The information of the main instruments used in the study is shown in Table 5.

[0231] Table 5 Instrument information

[0232] 1.3. Stability testing method

[0233] 1.3.1 Appearance

[0234] Wipe the sample bottle clean and visually inspect the color. Place it in a dark room under a clarity tester with the illumination adjusted to 1500 lx. Place the sample at the edge of the light shield (25 cm) and hold the neck of the sample bottle against a black and white background to visually inspect the clarity and visible foreign matter.

[0235] 1.3.2 pH value

[0236] Calibrate the pH meter with three standard solutions (pH 4.01, 7.00, and 9.21). Require the calibration slope to be between 95.0% and 105.0%, and the calibration zero drift to be between -60.0 mV and 60.0 mV. If the calibration value is outside this range, recalibrate. Aliquot 200 μL of sample and measure the pH value.

[0237] 1.3.3 Protein content

[0238] After the sample is evenly mixed, a small amount of 4 μL of sample is taken with a pipette and the absorbance of the sample at 280 nm is measured using Nano-300 and the concentration is calculated. The extinction coefficient is 1.373 AU*mL*mg -1 *cm -1 Repeat the measurement twice and take the mean value as the final result.

[0239] 1.3.4 Size Exclusion Chromatography Purity (SEC-HPLC)

[0240] SEC-HPLC analysis was performed using a Thermo Fisher Scientific U3000 high-performance liquid chromatograph (HPLC) with a TSKgel G3000SWXL column (5 μm, 7.8 mm × 300 mm). The column temperature was 25°C, the injection plate temperature was 2–8°C, and the mobile phase consisted of 50 mM phosphate buffer, 300 mM sodium chloride, pH 6.8 ± 0.1. The elution was isocratic at a flow rate of 1.0 ml / min and an elution time of 20 min. The detection wavelength was 280 nm, and the injection volume was 100 μg.

[0241] 1.3.5 icIEF

[0242] icIEF assays were performed using a ProteinSimple iCE3 (or equivalent) capillary isoelectric focusing (ICEF) analyzer and ProteinSimple fluorine-coated capillary tubing. Pharmalyte 3-10 and Pharmalyte 8-10.5 were used as ampholytes, with a low pI marker of 7.05 and a high pI marker of 9.50. The sample plate temperature was 10°C. Focusing stage 1 was performed at 1500 V for 1 minute, and at 3000 V for 10 minutes. Sample injection time was 60 seconds.

[0243] 1.3.6 Capillary electrophoresis purity (reduced CE-SDS)

[0244] Reducing capillary gel electrophoresis was performed using UV or diode array detection with uncoated fused silica capillaries (50 μm inner diameter). The test sample was diluted to 1 mg / ml with SDS sample buffer. 95 μl of the test solution (1 mg / ml) was added with 5 μl of 2-mercaptoethanol and vortexed. A blank control (95 μl) was added with 5 μl of 2-mercaptoethanol and vortexed. This was used as the reducing blank control for detection. Heavy and light chain percentages were calculated by area normalization.

[0245] 1.3.7 Capillary electrophoresis purity (non-reducing CE-SDS)

[0246] Reducing capillary gel electrophoresis was performed using UV or diode array detection and non-coated fused silica capillaries (50 μm inner diameter). The test sample was diluted to 1 mg / ml with SDS sample buffer. 95 μl of the test sample solution (1 mg / ml) was added to 5 μl of a 0.8 mol / L iodoacetamide aqueous solution and vortexed. A blank control (95 μl) was added to 5 μl of a 0.8 mol / L iodoacetamide aqueous solution and vortexed to mix. This was used as the non-reducing blank control for detection. The purity of the main peak was calculated by area normalization.

[0247] 1.3.8 MFI

[0248] The MFI test uses the ProteinSimple 5200 instrument, Bot1 automatic sample addition, 1ml disposable conductivity pipette tip for standardized sampling, particle detection range of 1-70μm, and injection volume of 1.5ml.

[0249] 1.3.9 Biological activity

[0250] Biological activity was determined using an antibody-mediated cytotoxicity (ADCC) cell-based assay. Target and effector cells were thawed and cultured. Target cells were added to a 96-well plate and incubated with the test article after gradient dilution. Effector cells were then added to the 96-well plate and incubated together. Luciferase was then added and fluorescence readings were taken after 5 minutes of incubation. A four-parameter fitting model was applied to generate a fitting curve and obtain the EC50 (50% maximum effect concentration) value. The relative activity of the test article was calculated as the EC50 of the reference article divided by the EC50 of the test article and multiplied by 100%.

[0251] Criteria for judging the stability of preparations

[0252] Stable after storage at, for example, about 5°C ± 3°C for at least 12 or 24 months, at about 25°C ± 2°C for at least 1, 2, 3 or 6 months, or at 40°C ± 2°C for 1 month:

[0253] (i) the main peak variation is less than 5% and / or the preparation has a purity greater than 95% as measured by SEC-HPLC;

[0254] (ii) the sum of the changes in the components of the protein in the formulation (the main component, the acidic component, and the basic component) relative to the initial value on storage day 0, as measured by the iCIEF method, does not exceed 40% and / or the change in the main component does not exceed 20%, for example, after storage at 40°C ± 2°C for 1 month, the sum of the changes does not exceed about 40% or the change in the main component does not exceed about 20%, or after storage at 25°C for 2 months, the sum of the changes does not exceed about 20% or the change in the main component does not exceed about 15%;

[0255] (iii) Subvisible / insoluble particles measured by MFI or light obscuration method, containing no more than 6,000 particles of 10 μm and larger per bottle, and no more than 600 particles of 25 μm and larger per bottle;

[0256] (iv) stable under shaking and / or freeze-thaw cycles;

[0257] (v) the percentage change in the light chain and heavy chain (LC+HC) peak area is less than 5%, or the percentage change in the main peak area is less than 5%, as measured by reduced CE-SDS or non-reduced CE-SDS for size isomers, and / or the preparation has a purity greater than 90%; and

[0258] (vi) The biological activity should be 70%-130% of the activity of the reference product.

[0259] Example 1. Preparation and purification of anti-CCR8 antibodies

[0260] The following novel anti-CCR8 antibodies that specifically bind to CCR8 were prepared and purified according to PCT patent application PCT / CN2022 / 136276, the contents of which are hereby incorporated by reference: Hu149-1, Hu149-2, Hu149-3, Hu149-4, Hu149-5, Hu149-6, Hu149-7, Hu149-8, Hu149-9, 11-24, Hu149-11G1, Hu149-11G1m, Hu149-11G1x, Hu149-12G1m, Hu149-12G1x, Hu348-1, Hu348-2, Hu348-3, Hu348-4, Hu348-5, Hu348-6, Hu348-7, Hu348-8, Hu348-9, Hu348-4-m2G1, Hu348-4-m2G1m and Hu348-4-m2G1x, 191E12H8, 234G9C12, 273H2G6, 348E2D11, 149F 2C10, 153D4G2, 160D1E3, 164G10D6, 204A2G12, 262C2G7, 499B1A5, 149F2C10_N2 8Q, 149F2C10_N28I, 149F2C10_N28S, 149F2C10_G29A, 149F2C10_G29I, 149F2C1 0_G29I, 149F2C10_G29V, 499B1A5_L28(NtoS), 499B1A5_L28(NtoY), 499B1A5_L 29(GtoA), 499B1A5_L51(MtoA), 499B1A5_H100D(MtoA), 499B1A5_H100D(MtoF). The variable region sequence characteristics are summarized in Tables 1 to 3 above, and the constant region comprises wild-type human IgG1 Fc (SEQ ID NO: 119), or human IgG1 Fc comprising S239D / I332E mutations (SEQ ID NO: 121, indicated by a G1x suffix), or human IgG1 Fc comprising L235V / F243L / R292P / Y300L / P396L mutations (SEQ ID NO: 120, indicated by a G1m suffix).

[0261] Example 2. Effect of buffer and its pH value on the stability of anti-CCR8 antibodies

[0262] This example evaluated the effects of buffer and pH on the stability of anti-CCR8 antibodies using Hu149-11G1m as an example. Solution pH and buffer are among the most important parameters affecting the physicochemical stability of biopharmaceuticals. pH modulates the charge distribution on protein surfaces, thereby influencing the attractive and repulsive forces within and between biopharmaceutical molecules. It also regulates interactions between biopharmaceuticals and other small molecules, such as excipients. Different buffers can also affect protein stability. Using a protein concentration of 10 mg / ml as an example, different buffers were prepared at different pH values ​​according to Table 6.

[0263] Table 6 pH and buffer solution prescription information

[0264] 2.1 Experimental methods

[0265] The purified product was replaced with the prepared buffer for each formulation and then diluted with the corresponding buffer to a target concentration of 10 mg / ml to obtain each formulation. After sterile filtration, the product was dispensed into 2 ml vials. Stability testing was performed at 5 ± 3°C, 25 ± 2°C / 60% ± 5% RH, and 40 ± 2°C / 75% ± 5% RH. Appearance, pH, protein concentration, SEC-HPLC, and icIEF were tested at the sampling points shown in the table below. The sampling points and test items for the stability tests are shown in Table 7.

[0266] Table 7 Sampling time and test items

[0267] 2.2 Stability test results and discussion

[0268] 1) Appearance

[0269] After being placed at 5±3℃, 25±2℃ and 40±2℃ for 4 weeks, the appearance of each prescription did not change significantly. They were all colorless and clear liquids with no obvious visible foreign matter.

[0270] 2) pH and protein concentration

[0271] The pH value test results and protein concentration of each prescription at different sampling points under 5±3℃, 25±2℃ and 40±2℃ did not change significantly, indicating that the pH value and protein concentration were relatively stable.

[0272] 3)SEC-HPLC purity

[0273] Figures 1 to 3 show the SEC-HPLC main peak purity graphs of formulations F1 to F12 prepared using antibody Hu149-11G1m from the above-mentioned antibodies as an example in the stability experiment under different temperature conditions. Compared to T0, each formulation remained relatively stable after 4 weeks at 5±3°C, showing no significant changes. The sample purity in the phosphate buffer system was slightly lower than that in the other three buffer systems (see Figure 1). After 4 weeks at 25°C±2°C, compared to T0 (main peak purity of each formulation ≥98.0%), with the exception of the phosphate buffer group (F10-F12, main peak purity at different pH values ​​decreased by approximately 1% to approximately 97.5%), the SEC-HPLC of the remaining formulations remained relatively stable (all at approximately 98.5%), showing no significant decrease. The phosphate buffer group formulation purity (main peak purity at different pH values ​​was 97.5%) was slightly lower than the purity of the remaining buffer groups formulations (main peak purity was approximately 98.5%) (see Figure 2). After being placed at 4℃±2℃ for 4 weeks, the purity of each formulation decreased compared with T0. In the histidine buffer system, there was no significant difference among the formulations, and the purity of the main peak was around 98%. Overall, the purity of the histidine buffer system (F7-F9) was significantly better than that of the other three buffer systems (see Figure 3).

[0274] 4)icIEF

[0275] Figures 4 to 6 show the icIEF main peak purity plots of formulations F1-F12 prepared in this example, using antibody Hu149-11G1m from the above-mentioned antibodies as an example, during stability experiments at different temperatures. Compared to T0, the main peak purity of each formulation remained relatively stable after 4 weeks at 5±3°C, showing no significant decrease (see Figure 4). After 4 weeks at 25±2°C, compared to T0, with the exception of F12 (7.5% phosphate), which showed a slight decrease in main peak purity (41.3%), the main peak purity of the remaining formulations remained relatively stable (all ≥45.0%), showing no significant change. The main peak purity of F8 (6.0% histidine) (47.3%) was slightly superior to that of the remaining formulations (all approximately 45.0%) (see Figure 5). After being placed at 40℃±2℃ for 4 weeks, the main peak purity of each formulation decreased significantly compared with T0. In the histidine buffer system, there was no significant difference among the formulations (the main peak purity at different pH values ​​was 38.2%, 37.8% and 37.6%, respectively). Overall, the main peak purity of the histidine buffer system (F7-F9) was significantly better than that of the other three buffer systems (see Figure 6).

[0276] 2.3 Summary of pH and buffer system screening

[0277] The results of pH and buffer system screening showed that: at 5±3℃, the protein remained relatively stable in several alternative buffer systems without significant changes; at 25±2℃, except for the phosphate buffer group, the SEC-HPLC of the other formulations remained relatively stable without significant decline, and the icIEF main peak purity of the F8 formulation (histidine 6.0) was slightly better than that of the other formulations; at 40±2℃, the main peak purity of each formulation decreased significantly, and the purity of the histidine buffer group (SEC-HPLC and icIEF) was significantly better than that of the other three buffer groups.

[0278] Example 3. Effect of Stabilizers on the Stability of Anti-CCR8 Antibodies

[0279] 3.1 Stabilizer Screening Prescription Information

[0280] Common protein protectants or stabilizers, such as sugars, polyols, and amino acids, protect proteins through a mechanism of "preferential exclusion." These excipients are preferentially excluded from the protein surface, increasing the protein's chemical potential energy. Due to the increased surface area after protein denaturation and unfolding, interactions with excipients increase, leading to a higher chemical potential energy. This increases the activation energy required for conformational denaturation, shifting the equilibrium between the native and denatured conformations of the protein toward the native conformation, thereby increasing the protein's conformational stability.

[0281] Nonionic surfactants can inhibit protein aggregation. This may be because surfactants tend to align at the air-liquid interface, thereby dislodging proteins from the interface and inhibiting protein aggregation and denaturation. Commonly used surfactants include polysorbate 80 and polysorbate 20. This surfactant was the preferred surfactant for subsequent experiments.

[0282] Taking polysorbate 80 as a surfactant, 20 mM histidine as a buffer, pH 6.0, and a protein concentration of 50 mg / ml as an example, the formulation design prepared using the antibody Hu149-11G1m is shown in the table below to examine the effects of different stabilizers on protein stability.

[0283] Table 1 Prescription information for stabilizer screening

[0284] 3.2 Experimental methods

[0285] After adding different amounts of excipients to the purified protein, the sample was diluted to the target concentration with the corresponding buffer to obtain each formulation. After sterile filtration, it was aliquoted into 2 ml vials and stored at 5 ± 3°C, 25 ± 2°C / 60% ± 5% RH, and 40 ± 2°C / 75% ± 5% RH under freeze-thaw conditions for stability testing. Appearance, pH, protein concentration, SEC-HPLC, icIEF, and MFI were tested. The sampling points and test items for the stability test samples are shown in Table 9.

[0286] Table 2 Sampling time and test items

[0287] Note: + means sampling test; - means no sampling test;

[0288] 3.3 Results and Analysis

[0289] 1) Appearance

[0290] During stability testing at 5±3°C for 8 weeks, 25±2°C for 8 weeks, and 40±2°C for 4 weeks, the formulations remained colorless, clear liquids with no visible foreign matter. Furthermore, after repeated freeze-thaw cycles, the formulations remained colorless, clear liquids with no visible foreign matter.

[0291] 2) pH and protein concentration

[0292] During the 8-week stability tests at 5±3°C, 8-week stability tests at 25±2°C, and 4-week stability tests at 40±2°C, the pH values ​​and protein concentrations at different sampling points did not change significantly, indicating that the pH and protein concentrations were relatively stable. Furthermore, after repeated freeze-thaw cycles, the pH values ​​and protein concentrations at different sampling points did not change significantly compared to T0, indicating that the pH and protein concentrations were relatively stable.

[0293] 3)SEC-HPLC purity

[0294] Figures 7 to 10 show the SEC-HPLC main peak purity graphs of the formulations F1-F4 prepared in this embodiment using the antibody Hu149-11G1m among the above antibodies as an example in the stability test under different temperature conditions and the repeated freeze-thaw stability test. After 8 weeks of observation under the stability test conditions of 5±3°C and 25±2°C, the SEC-HPLC main peak purity of each formulation containing different excipients did not change significantly, indicating that the SEC-HPLC purity of each formulation after the excipient screening was relatively stable after 8 weeks of storage at 5±3°C and 25±2°C (see Figures 7 and 8). In the 4-week high temperature stability test at 40±2°C, the SEC-HPLC main peak purity of each formulation showed a downward trend, and there was no significant difference between the formulations (see Figure 9).

[0295] In the repeated freeze-thaw stability test, except for the F3 formulation (mannitol), the purity of the main peak of SEC-HPLC of the other formulations did not decrease significantly (see Figure 10).

[0296] 4)icIEF

[0297] Figures 11-14 show the icIEF main peak purity plots for formulations F1-F4, prepared using Hu149-11G1m from the aforementioned antibodies, during stability tests at different temperatures and repeated freeze-thaw stability tests. After 8 weeks of stability testing at 5±3°C and 25±2°C, the icIEF main peak purity of each formulation containing different excipients remained relatively stable compared to T0, with no significant differences between formulations (see Figures 11 and 12). In the 4-week high-temperature stability test at 40±2°C, the icIEF main peak purity of each formulation containing different excipients showed a significant downward trend compared to T0, with the formulation containing 7% (w / v) sucrose exhibiting slightly higher main peak purity than the other formulations (see Figure 13). In the repeated freeze-thaw stability test, the main peak purity of each formulation remained unchanged compared to T0 (see Figure 14).

[0298] 5) MFI

[0299] Compared to T0, no significant increase in insoluble particulates was observed in any formulation during the 8-week stability tests at 5±3°C and 25±2°C. Compared to T0, insoluble particulates increased to some extent in all formulations at 40±2°C, but remained within the pharmacopoeial range. In the repeated freeze-thaw stability test, no significant increase in insoluble particulates was observed in any formulation, remaining within the pharmacopoeial range, with no significant differences between formulations.

[0300] 3.4 Summary of Stabilizer Screening

[0301] In the excipient screening test, the effects of different stabilizers (sucrose, trehalose, mannitol, sucrose / arginine hydrochloride) on the stability of the preparation were investigated. The test results showed that under the stability test conditions of 5°C, 25°C and 40°C, there was no significant difference in the SEC-HPLC main peak purity between the formulations containing sucrose and those containing other excipients. Freeze-thawing had no significant effect on the SEC-HPLC purity of the samples (except for the F3 formulation). Under high temperature conditions, the icIEF main peak purity of the formulation containing 7% (w / v) sucrose was slightly better than that of the other formulations.

[0302] Example 4. Effect of surfactant concentration on the stability of anti-CCR8 antibodies

[0303] 4.1 Surfactant Prescribing Information

[0304] Using polysorbate 80 (PS80) as a surfactant, 20 mM histidine as a buffer, pH 6.0, a protein concentration of 50 mg / ml, and 7% (w / v) sucrose as a stabilizer, the formulation was designed as shown in Table 10 below to investigate the effects of different surfactant concentrations on protein stability.

[0305] Table 3 Surfactant screening prescription information

[0306] 4.2 Experimental methods

[0307] After adding the corresponding excipients and surfactants to the purified protein, the protein was diluted to the target concentration with the corresponding buffer to obtain samples of each formulation. After sterile filtration, the samples were aliquoted into 2 ml vials and placed under freeze-thaw conditions at 5 ± 3°C, 25 ± 2°C / 60% ± 5% RH, and 40 ± 2°C / 75% ± 5% RH for stability testing. Appearance, pH, protein concentration, SEC-HPLC, icIEF, and MFI were tested. The sampling points and test items for the stability test samples are shown in Table 11.

[0308] Table 4 Sampling time and test items

[0309] Note: + means sampling test; - means no sampling test;

[0310] 4.3 Results and Analysis

[0311] 1) Appearance

[0312] After 12 weeks of accelerated stability testing at 5±3°C and 25±2°C, each formulation remained as a colorless, clear liquid with no visible foreign matter. Furthermore, after 4 weeks of high-temperature stability testing at 40±2°C and repeated freeze-thaw stability testing, each formulation remained as a colorless, clear liquid with no visible foreign matter.

[0313] 2) pH and protein concentration

[0314] After 12 weeks of accelerated stability testing at 5±3°C and 25±2°C, the pH values ​​and protein concentrations at different sampling points did not change significantly, indicating that the pH and protein concentrations were relatively stable. Furthermore, in the high-temperature stability testing at 40±2°C for 4 weeks and the repeated freeze-thaw stability testing, the pH values ​​and protein concentrations at different sampling points did not change significantly, indicating that the pH and protein concentrations were relatively stable.

[0315] 3)SEC-HPLC purity

[0316] 15-17 show the SEC-HPLC main peak purity graphs of the formulations F1-F3 prepared using the antibody Hu149-11G1m among the above antibodies in this example in the stability experiments under different temperature conditions.

[0317] After 12 weeks of observation at 5±3°C, the SEC-HPLC main peak purity of each formulation containing different polysorbate concentrations did not change significantly compared to T0, indicating that the SEC-HPLC purity of each formulation screened for surfactant materials was relatively stable after 12 weeks of storage at 5±3°C (see Figure 15). After 12 weeks of accelerated stability testing at 25±2°C, the main peak purity of each formulation containing different polysorbate concentrations decreased (the main peak purity at the three different polysorbate concentrations was 98.3%, 98.2%, and 98.1%, respectively) compared to T0 (the main peak purity at different polysorbate concentrations was 99.1%), with no significant differences between the formulations (see Figure 16). After 4 weeks of observation at 40±2°C, the SEC-HPLC main peak purity of each formulation containing different polysorbate concentrations decreased compared to T0. The higher the polysorbate concentration, the greater the decrease in SEC-HPLC main peak purity. Under repeated freeze-thaw conditions, the SEC-HPLC main peak purity of each formulation remained relatively stable, with no significant changes (see Figure 17). Under repeated freeze-thaw conditions, the SEC-HPLC main peak purity of each formulation remained relatively stable, with no significant changes.

[0318] 4)icIEF

[0319] 18 to 20 show the icIEF main peak purity graphs of the formulations F1 to F3 prepared using the antibody Hu149-11G1m among the above antibodies in this example in the stability experiments under different temperature conditions.

[0320] After 12 weeks of testing at 5±3°C, the main peak purity of the icIEF for each formulation containing different polysorbate concentrations remained stable compared to T0 (see Figure 18). After 12 weeks of accelerated stability testing at 25±2°C, the main peak purity of the icIEF for each formulation containing different polysorbate concentrations decreased compared to T0 (main peak purity of 60.7%, 60.9%, and 60.0%, respectively) (58.6%, 56.9%, and 55.5%, respectively), with no significant differences between the formulations (see Figure 19). After 4 weeks of testing at 40±2°C, the main peak purity of the icIEF for each formulation containing different polysorbate concentrations decreased significantly compared to T0, with no significant differences between the formulations. Under repeated freeze-thaw conditions, the main peak purity of each formulation remained stable, with no significant changes (see Figure 20).

[0321] 5) MFI

[0322] Compared to T0, after 12 weeks at 5±3°C, no significant increase in insoluble particulates was observed for each formulation, remaining within the pharmacopoeial range. Compared to T0, after 12 weeks of accelerated stability testing at 25±2°C, all formulations remained within the pharmacopoeial range. Formulation F2 (polysorbate concentration 0.04%) had slightly fewer insoluble particulates than the other two formulations. Compared to T0, during the 40±2°C high-temperature stability test, no significant increase in insoluble particulates was observed for each formulation. Formulation F2 (polysorbate concentration 0.04% (w / v)) had fewer insoluble particulates than the other two formulations. A slight increase in insoluble particulates was observed after repeated freeze-thaw cycles, remaining within the pharmacopoeial range.

[0323] 4.4 Summary of surfactant concentration screening

[0324] In the high-temperature stability test at 40±2°C, the higher the polysorbate 80 content, the greater the decrease in the purity of the SEC-HPLC main peak. The formulation containing 0.04% (w / v) polysorbate 80 had better insoluble particles than the other two formulations. At the same time, in the long-term and repeated freeze-thaw stability tests, there was no significant difference in the effects of three different polysorbate 80 concentrations (0.02%, 0.04%, and 0.06%) on protein stability.

[0325] Example 5. Example of anti-CCR8 antibody stability experiment

[0326] 5.1 Example Anti-CCR8 Antibody Preparation Information

[0327] Using polysorbate 80 (PS80) as a surfactant, 20 mM histidine as a buffer, pH 6.0, taking the antibody Hu149-11G1m as an example with a protein concentration of 50 mg / ml, 7% (w / v) sucrose as a stabilizer, and polysorbate 80 as a surfactant (e.g., 0.04% (w / v)), two batches of long-term, accelerated, and high-temperature and high-humidity forced stability studies were carried out in accordance with ICH (The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) Q5C (Stability Testing of Biotechnological / Biological Products) and the "Guidelines for Stability Testing of Biological Products" (Chinese Pharmacopoeia, Part IV, 9402, current edition).

[0328] 5.2 Stability test and conclusion

[0329] 1) Molecular size heterogeneity (SEC-HPLC method)

[0330] Molecular size heterogeneity of two batches of the formulation was assessed by SEC-HPLC under long-term, accelerated, and forced high-temperature and high-humidity conditions. After 12 months of storage at 5°C ± 3°C, no significant trend was observed, meeting the acceptance criteria. After 6 months of storage at 25°C ± 2°C, 60% ± 5% RH, no significant trend was observed. After 1 month of storage at 40°C ± 2°C, 75% ± 5% RH, the average monomer content decreased by less than 5%, and no significant change in aggregate content was observed. Good batch-to-batch consistency was observed.

[0331] 2) Molecular size heterogeneity (CE-SDS method)

[0332] Molecular size heterogeneity of two finished product batches was assessed by non-reduced and reduced CE-SDS methods under long-term, accelerated, and forced high-temperature and high-humidity conditions. After 12 months of storage at 5°C ± 3°C, no significant trend was observed, and all batches met the acceptance criteria. After 6 months of storage at 25°C ± 2°C, 60% ± 5% RH, no significant trend was observed. After 1 month of storage at 40°C ± 2°C, 75% ± 5% RH, intact IgG purity was greater than 90% as determined by non-reduced CE-SDS, while (light chain + heavy chain) purity decreased slightly as determined by reduced CE-SDS. Good batch-to-batch consistency was observed.

[0333] 3) Charge heterogeneity (icIEF method)

[0334] Charge heterogeneity of two finished product batches was evaluated by icIEF under long-term, accelerated, and forced high-temperature and high-humidity conditions. After 12 months of storage at 5°C ± 3°C, no significant trend was observed, meeting the acceptance criteria. After 6 months of storage at 25°C ± 2°C, 60% ± 5% RH, the main peak area percentage did not exceed 10%, also meeting the acceptance criteria. After 1 month of storage at 40°C ± 2°C, 75% ± 5% RH, the main peak area percentage did not exceed 20%, also meeting the acceptance criteria. Good batch-to-batch consistency was observed.

[0335] 4) Biological activity

[0336] The biological activity of two batches of finished product was evaluated using a cell-based, antibody-mediated cytotoxicity assay under long-term, accelerated, and forced conditions of high temperature and humidity. After 12 months of storage at -5°C ± 3°C, no significant trend was observed, and all batches met the acceptance criteria. After 6 months of storage at 25°C ± 2°C, 60% ± 5% RH, no significant trend was observed. After 1 month of storage at 40°C ± 2°C, 75% ± 5% RH, no significant trend was observed. Good batch-to-batch consistency was observed.

[0337] 5) Protein content

[0338] Protein concentration in two batches of finished product was assessed by UV absorbance under long-term, accelerated, and forced conditions of high temperature and humidity. No significant trend was observed after 12 months of storage at 5°C ± 3°C, 60% ± 5% RH, or 6 months of storage at 25°C ± 2°C, 60% ± 5% RH. No significant trend was observed after 1 month of storage at 40°C ± 2°C, 75% ± 5% RH. Good batch-to-batch consistency was observed.

[0339] 6) Appearance

[0340] Appearance, including description, solution color, clarity, and visible foreign matter, was visually inspected under long-term, accelerated, and forced high-temperature, high-humidity conditions. Two batches of finished product were evaluated for color, clarity, and visible foreign matter. No significant trend was observed after 12 months of storage at 5°C ± 3°C; no significant trend was observed after 6 months of storage at 25°C ± 2°C, 60% ± 5% RH; and no significant trend was observed after 1 month of storage at 40°C ± 2°C, 75% ± 5% RH. Good batch-to-batch consistency was observed.

[0341] 7) pH

[0342] The pH of two finished product batches was evaluated under long-term, accelerated, and forced conditions of high temperature and humidity. No significant trend was observed after 12 months of storage at 5°C ± 3°C; no significant trend was observed after 6 months of storage at 25°C ± 2°C, 60% ± 5% RH; and no significant trend was observed after 1 month of storage at 40°C ± 2°C, 75% ± 5% RH. Good batch-to-batch consistency was observed.

[0343] 8) Insoluble particles

[0344] Two batches of finished product were evaluated for insoluble particulate matter under long-term, accelerated, and forced conditions of high temperature and humidity. After 12 months of storage at 5°C ± 3°C, no significant trend was observed, and all batches met the acceptance criteria. After 6 months of storage at 25°C ± 2°C, 60% ± 5% RH, no significant trend was observed. After 1 month of storage at 40°C ± 2°C, 75% ± 5% RH, no significant trend was observed. Batch-to-batch consistency was excellent.

[0345] While the exemplary embodiments of the present invention have been described above, it should be understood by those skilled in the art that these disclosures are merely exemplary and that various other substitutions, adaptations, and modifications may be made within the scope of the present invention. Therefore, the present invention is not limited to the specific embodiments listed herein.

Claims

1. A liquid antibody preparation comprising (i) anti-CCR8 antibodies or antigen-binding fragments; (ii) a buffer; (iii) stabilizers; and (iv) Surfactant.

2. The liquid antibody formulation of claim 1, wherein the concentration of the anti-CCR8 antibody or antigen-binding fragment is about 1 to about 200 mg / mL, preferably about 1 mg / mL to about 100 mg / mL, for example about 1, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 mg / mL.

3. The liquid antibody formulation according to any one of claims 1-2, wherein the buffer is selected from the group consisting of histidine-histidine hydrochloride buffer system, citric acid-sodium citrate buffer system, acetic acid-sodium acetate buffer system, phosphate buffer system and combinations thereof; preferably, the buffer is selected from the group consisting of histidine, histidine hydrochloride and combinations thereof.

4. The liquid antibody formulation according to any one of claims 1 to 3, wherein the concentration of the buffer is about 0.1-100 mM, preferably about 1-50 mM, such as about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 mM.

5. The liquid antibody formulation according to any one of claims 1 to 4, wherein the stabilizer is selected from sugars, polyols, amino acids and combinations thereof, preferably, the stabilizer is selected from sucrose, trehalose, mannitol, arginine hydrochloride and combinations thereof.

6. The liquid antibody formulation according to any one of claims 1 to 5, wherein the concentration of the stabilizer is about 0.1-20% (w / v), preferably about 1-10% (w / v), for example about 1% (w / v), 2% (w / v), 3% (w / v), 4% (w / v), 5% (w / v), 6% (w / v), 7% (w / v), 8% (w / v), 9% (w / v) or 10% (w / v).

7. The liquid antibody formulation according to any one of claims 1 to 6, wherein the surfactant is a non-ionic surfactant, for example selected from polysorbate surfactants such as polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 80, poloxamer, polyethylene glycol and combinations thereof, preferably polysorbate 80.

8. The liquid antibody formulation according to any one of claims 1 to 7, wherein the concentration of the surfactant is about 0.001-0.5% (w / v), preferably about 0.01-0.1% (w / v) or 0.02-0.06% (w / v), for example about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09 or 0.1% (w / v).

9. The liquid antibody formulation according to any one of claims 1 to 8, wherein the pH of the liquid formulation is about 4-8, such as about 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 or 8.

10. A liquid antibody preparation comprising an anti-CCR8 antibody or antigen-binding fragment, a buffer, a stabilizer, and a surfactant, wherein the buffer is selected from a histidine-histidine hydrochloride buffer system, a citric acid-sodium citrate buffer system, an acetic acid-sodium acetate buffer system, a phosphate buffer system, and a combination thereof, the stabilizer is selected from sucrose, trehalose, mannitol, arginine hydrochloride, and a combination thereof, and the surfactant is selected from a polysorbate surfactant such as polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80, poloxamer, polyethylene glycol, and a combination thereof; preferably, the pH of the antibody preparation is about 5-7.

11. The liquid antibody formulation according to claim 10, comprising about 1-200 mg / ml anti-CCR8 antibody or antigen-binding fragment, about 1-100 mM buffer, about 0.1-20% (w / v) stabilizer, about 0.01-0.5% (w / v) surfactant, pH of about 5-7, the buffer is selected from histidine-histidine hydrochloride buffer system, citric acid-sodium citrate buffer system, acetic acid-sodium acetate buffer system, phosphate buffer system and combinations thereof, the stabilizer is selected from sucrose, trehalose, mannitol, arginine hydrochloride and combinations thereof, the surfactant is selected from polysorbate surfactants such as polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 80, poloxamer, polyethylene glycol and combinations thereof.

12. The liquid antibody formulation according to claim 10, comprising about 1-100 mg / ml anti-CCR8 antibody or antigen-binding fragment, about 1-50 mM buffer, about 1-10% (w / v) stabilizer, about 0.01-0.1% (w / v) surfactant, pH of about 5-7, the buffer is selected from histidine-histidine hydrochloride buffer system, citric acid-sodium citrate buffer system, acetic acid-sodium acetate buffer system, phosphate buffer system and combinations thereof, the stabilizer is selected from sucrose, trehalose, mannitol, arginine hydrochloride and combinations thereof, the surfactant is selected from polysorbate surfactants such as polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 80, poloxamer, polyethylene glycol and combinations thereof.

13. The liquid antibody formulation according to claim 10, comprising about 1-200 mg / ml anti-CCR8 antibody or antigen-binding fragment, about 1-100 mM histidine-histidine hydrochloride buffer system, about 0.1-20% (w / v) sucrose, about 0.01-0.5% (w / v) polysorbate 80, and a pH of about 5-7.

14. The liquid antibody formulation according to claim 13, comprising about 1-100 mg / ml anti-CCR8 antibody or antigen-binding fragment, about 1-50 mM histidine-histidine hydrochloride buffer system, about 1-10% (w / v) sucrose, about 0.01-0.1% (w / v) polysorbate 80, and a pH of about 5-7.

15. The liquid antibody formulation according to claim 14, comprising about 10-50 mg / ml anti-CCR8 antibody or antigen-binding fragment, about 1-50 mM histidine-histidine hydrochloride buffer system, about 1-10% (w / v) sucrose, about 0.01-0.1% (w / v) polysorbate 80, and a pH of about 5-7.

16. The liquid antibody formulation according to claim 15, comprising about 10-50 mg / ml anti-CCR8 antibody or antigen-binding fragment, about 20 mM histidine-histidine hydrochloride buffer system, about 7% (w / v) sucrose, about 0.02-0.06% (w / v) polysorbate 80, and a pH of about 5-7.

17. The liquid antibody formulation according to claim 16, comprising about 50 mg / ml anti-CCR8 antibody or antigen-binding fragment, about 20 mM histidine-histidine hydrochloride buffer system, about 7% (w / v) sucrose, about 0.02-0.06% (w / v) polysorbate 80, and a pH of about 5-7.

18. The liquid antibody formulation according to claim 17, comprising about 50 mg / ml anti-CCR8 antibody or antigen-binding fragment, about 20 mM histidine-histidine hydrochloride buffer system, about 7% (w / v) sucrose, about 0.04% (w / v) polysorbate 80, and a pH of about 6.

19. The liquid antibody preparation according to any one of claims 1 to 18, wherein the anti-CCR8 antibody or antigen-binding fragment comprises a heavy chain variable region VH and / or a light chain variable region VL, wherein (a) the VH comprises (i) three complementary determining regions (CDRs) in any one of the VHs selected from SEQ ID NO: 1, 3, 4, 5, 6, 7, 11, 12, 26, 28, 30, 32, 34, 36, 37, 39, 41, 54-59, 61 and 66-70, (ii) a combination of a HCDR1 of an amino acid sequence selected from the group consisting of SEQ ID NOs: 13, 71, 83, 115 and 117, a HCDR2 of an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 72, 77, 84, 89, 91, 92, 97, 114, 116 and 118, and a HCDR3 of an amino acid sequence selected from the group consisting of SEQ ID NOs: 15, 19-22, 73, 78, 81, 85, 93, 98, 112 and 113; or (iii) a sequence comprising at least one and no more than 5, 4, 3, 2 or 1 amino acid changes (preferably amino acid substitutions, preferably conservative substitutions) in each of the three CDRs relative to the sequence of (i) or (ii); and / or (b) the VL comprises (i) three CDRs in any one of the VLs selected from SEQ ID NOs: 2, 8, 9, 10, 27, 29, 31, 33, 35, 38, 40, 42-53, 60, and 62-65, (ii) a combination of a LCDR1 of an amino acid sequence selected from SEQ ID NOs: 16, 74, 79, 86, 90, 94, 99 and 102-109, a LCDR2 of an amino acid sequence selected from SEQ ID NOs: 17, 75, 80, 87, 95, 100, 110 and 111, and a LCDR3 of an amino acid sequence selected from SEQ ID NOs: 18, 23-25, 76, 82, 88, 96 and 101; or (iii) a sequence comprising at least one and no more than 5, 4, 3, 2 or 1 amino acid changes (preferably amino acid substitutions, preferably conservative substitutions) in each of the three CDRs relative to the sequence of (i) or (ii).

20. The liquid antibody formulation of claim 19, wherein the HCDR1 comprises a sequence selected from SEQ ID NOs: 13 and 115, the HCDR2 comprises a sequence selected from SEQ ID NOs: 14, 89 and 114, and the HCDR3 comprises a sequence selected from SEQ ID NOs: 15 and 19-22; the LCDR1 comprises a sequence selected from SEQ ID NOs: 16, 90 and 102-106, the LCDR2 comprises a sequence of SEQ ID NO: 17, and the LCDR3 comprises a sequence selected from SEQ ID NOs: 18 and 23-25.

21. The liquid antibody preparation according to claim 19, wherein The HCDR1 comprises a sequence selected from SEQ ID NOs: 83 and 117, the HCDR2 comprises a sequence selected from SEQ ID NOs: 84, 116 and 118, and the HCDR3 comprises a sequence of SEQ ID NO: 85; The LCDR1 comprises the sequence of SEQ ID NO:86, LCDR2 comprises the sequence of SEQ ID NO:87, and LCDR3 comprises the sequence of SEQ ID NO:

88.

22. The liquid antibody formulation of claim 19, wherein the HCDR1, the HCDR2, and the HCDR3 are an amino acid sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15; SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 19; SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 20; SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 21; SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 22; SEQ ID NO: 71, SEQ ID NO: 72, and SEQ ID NO: 73; SEQ ID NO: 71, SEQ ID NO: 77, and SEQ ID NO: 78; SEQ ID NO: 71, SEQ ID NO: 72, and SEQ ID NO: 81; SEQ ID NO: 83, SEQ ID NO: 84, and SEQ ID NO: 85; SEQ ID NO: 13, SEQ ID NO: 89, and SEQ ID NO:

90. NO:15; SEQ ID NO:13, SEQ ID NO:91 and SEQ ID NO:15; SEQ ID NO:71, SEQ ID NO:92 and SEQ ID NO:93; SEQ ID NO:13, SEQ ID NO:97 and SEQ ID NO:98; SEQ ID NO:13, SEQ ID NO:97 and SEQ ID NO:112; SEQ ID NO:13, SEQ ID NO:97 and SEQ ID NO:113; SEQ ID NO:13, SEQ ID NO:114 and SEQ ID NO:15; SEQ ID NO:115, SEQ ID NO:114 and SEQ ID NO:15; SEQ ID NO:83, SEQ ID NO:116 and SEQ ID NO:85; SEQ ID NO:117, SEQ ID NO:116 and SEQ ID NO:85; and SEQ ID NO:83, SEQ ID NO:118 and SEQ ID NO:85; The LCDR1, the LCDR2 and the LCDR3 are an amino acid sequence selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18; SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 23; SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 24; SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 25; SEQ ID NO: 74, SEQ ID NO: 75 and SEQ ID NO: 76; SEQ ID NO: 79, SEQ ID NO: 80 and SEQ ID NO: 76; SEQ ID NO: 79, SEQ ID NO: 75 and SEQ ID NO: 82; SEQ ID NO: 86, SEQ ID NO: 87 and SEQ ID NO: 88; SEQ ID NO: 90, SEQ ID NO: 17 and SEQ ID NO: 18; SEQ ID NO: 94, SEQ ID NO: 95 and SEQ ID NO: 96; SEQ ID NO: 79, SEQ ID NO: 80 and SEQ ID NO: 86; NO:75 and SEQ ID NO:76; SEQ ID NO:99, SEQ ID NO:100 and SEQ ID NO:101; SEQ ID NO:101, SEQ ID NO:17 and SEQ ID NO:18; SEQ ID NO:103, SEQ ID NO:17 and SEQ ID NO:18; SEQ ID NO:104, SEQ ID NO:17 and SEQ ID NO:18; SEQ ID NO:105, SEQ ID NO:17 and SEQ ID NO:18; SEQ ID SEQ ID NO:106, SEQ ID NO:17, and SEQ ID NO:18; SEQ ID NO:107, SEQ ID NO:100, and SEQ ID NO:101; SEQ ID NO:108, SEQ ID NO:100, and SEQ ID NO:101; SEQ ID NO:109, SEQ ID NO:100, and SEQ ID NO:101; and SEQ ID NO:99, SEQ ID NO:111 and SEQ ID NO:

101.

23. The liquid antibody formulation of claim 20, wherein the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 are an amino acid sequence selected from the group consisting of SEQ ID NOs: 13, 14, 15, 16, 17 and 18; SEQ ID NOs: 13, 14, 19, 16, 17 and 18; SEQ ID NOs: 13, 14, 20, 16, 17 and 18; SEQ ID NOs: 13, 14, 21, 16, 17 and 18; SEQ ID NOs: 13, 14, 22, 16, 17 and 18; SEQ ID NOs: 13, 14, 15, 16, 17 and 23; SEQ ID NOs: 13, 14, 15, 16, 17 and 24; SEQ ID NOs: 13, 14, 15, 16, 17 and 25; NO:13, 14, 19, 16, 17 and 23; SEQ ID NO:13, 14, 20, 16, 17 and 23; SEQ ID NO:13, 14, 21, 16, 17 and 23; SEQ ID NO:13, 14, 22, 16, 17 and 23; SEQ ID NO:13, 89, 15, 90, 17 and 18; SEQ ID NO:13, 89, 15, 102, 17 and 18; SEQ ID NO:13, 89, 15, 103, 17 and 18; SEQ ID NO:13, 89, 15, 104, 17 and 18; SEQ ID NO:13, 89, 15, 16, 17 and 18; SEQ ID NO:13, 89, 15, 105, 17 and 18; SEQ ID NO:13, 89, 15, 106, 17 and 18; ID NOs: 13, 114, 15, 16, 17 and 18; and SEQ ID NOs: 115, 114, 15, 16, 17 and 18.

24. The liquid antibody formulation of claim 22, wherein the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 are an amino acid sequence selected from the group consisting of SEQ ID NOs: 83, 84, 85, 86, 87 and 88; SEQ ID NOs: 83, 116, 85, 86, 87 and 88; SEQ ID NOs: 117, 116, 85, 86, 87 and 88; and SEQ ID NOs: 83, 118, 85, 86, 87 and 88.

25. The liquid antibody preparation according to claim 19, wherein the anti-CCR8 antibody or antigen-binding fragment comprises a heavy chain variable region VH and / or a light chain variable region VL, wherein: (a) the heavy chain variable region VH comprises or consists of an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, or 100% identical to an amino acid sequence selected from ID NO: 1, 3, 4, 5, 6, 7, 11, 12, 26, 28, 30, 32, 34, 36, 37, 39, 41, 54-59, 61, and 66-70; and / or (b) the light chain variable region VL comprises or consists of an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, or 100% identical to an amino acid sequence selected from SEQ ID NO: 2, 8, 9, 10, 27, 29, 31, 33, 35, 38, 40, 42-53, 60 and 62-65.

26. The liquid antibody preparation according to claim 24, wherein the anti-CCR8 antibody or antigen-binding fragment comprises a heavy chain variable region VH and a light chain variable region VL, wherein the heavy chain variable region VH and the light chain variable region VL respectively comprise an amino acid sequence selected from the following group: SEQ ID NOs: 1 and 2; SEQ ID NOs: 3 and 2; SEQ ID NOs: 4 and 2; SEQ ID NOs: 5 and 2; SEQ ID NOs: 6 and 2; SEQ ID NOs: 7 and 2; SEQ ID NOs: 1 and 8; SEQ ID NOs: 1 and 9; SEQ ID NOs: 1 and 10; SEQ ID NOs: 3 and 8; SEQ ID NOs: 4 and 8; SEQ ID NOs: 5 and 8; SEQ ID NOs: 6 and 8; SEQ ID NOs: 11 and 8; SEQ ID NOs: 12 and 8; SEQ ID NOs: 34 and 35; SEQ ID NOs: 34 and 43; SEQ ID NOs: 34 and 44; SEQ ID NOs: 34 and 45; SEQ ID NOs: 34 and 46; SEQ ID NOs: 34 and 47; SEQ ID NO:34 and 48; SEQ ID NO:56 and 2; SEQ ID NO:57 and 2; SEQ ID NO:58 and 2; SEQ ID NO:59 and 2; SEQ ID NO:56 and 60; SEQ ID NO:57 and 60; and SEQ ID NO:58 and 60; and SEQ ID NO:59 and 60.

27. The liquid antibody preparation according to claim 25, wherein the heavy chain variable region VH and the light chain variable region VL respectively comprise an amino acid sequence selected from the following group: SEQ ID NOs: 32 and 33; SEQ ID NOs: 61 and 62; SEQ ID NOs: 61 and 63; SEQ ID NOs: 61 and 64; SEQ ID NOs: 61 and 65; SEQ ID NOs: 66 and 62; SEQ ID NOs: 67 and 62; SEQ ID NOs: 68 and 62; SEQ ID NOs: 69 and 62; and SEQ ID NOs: 70 and 62.

28. The liquid antibody formulation according to any one of claims 1 to 18, wherein the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of the anti-CCR8 antibody or antigen-binding fragment correspond to SEQ ID NOs: 13, 14, 19, 16, 17 and 18, respectively.

29. The liquid antibody formulation according to any one of claims 1 to 28, wherein the antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a humanized antibody, a chimeric antibody, and a combination thereof.

30. The liquid antibody formulation according to any one of claims 1-28, wherein the antigen binding fragment is scFv, Fab', single chain Fab (scFab'), Fd or F(ab')2, sFC or VHH.

31. The liquid antibody formulation of any one of claims 1-29, wherein the antibody or antigen-binding fragment comprises an IgG1 framework.

32. The liquid antibody formulation of claim 31 , wherein the antibody or antigen-binding fragment comprises one or more mutations in the Fc region, wherein the one or more mutations comprise an S239D mutation, an I332E mutation, an L235V mutation, an F243L mutation, an R292P mutation, a Y300L mutation, a P396L mutation, or a combination thereof.

33. The liquid antibody formulation of claim 32, wherein the one or more mutations enhance antibody-dependent cellular cytotoxicity.

34. The liquid antibody formulation of claim 1, comprising about 1-200 mg / ml anti-CCR8 antibody or antigen-binding fragment, about 0.1-100 mM buffer, about 0.1-20% (w / v) sugar or polyol stabilizer or amino acid stabilizer or a combination thereof, about 0.01-0.5% (w / v) surfactant, and a pH of about 4.0-8.0, wherein HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the anti-CCR8 antibody or antigen-binding fragment correspond to SEQ ID NOs: 13, 14, 19, 16, 17 and 18, respectively.

35. The liquid antibody preparation according to any one of claims 1 to 34, wherein The formulation is stable after storage, for example, at least 12 or 24 months at about 5°C ± 3°C, at least 1, 2, 3 or 6 months at about 25°C ± 2°C, or at least 1 month at 40°C ± 2°C, preferably having one or more of the following characteristics: (i) the main peak variation is less than 5% and / or the preparation has a purity greater than 95% as measured by SEC-HPLC; (ii) as measured by the iCIEF method, the sum of the changes in the components of the protein in the formulation (main component, acidic component and alkaline component) does not exceed 40% and / or the change in the main component does not exceed 20% relative to the initial value on storage day 0, for example, after storage at 40°C ± 2°C for 1 month, the sum of the changes does not exceed about 40% or the change in the main component does not exceed about 20%, or after storage at 25°C for 2 months, the sum of the changes does not exceed about 20% or the change in the main component does not exceed about 15%; (iii) Subvisible / insoluble particles measured by MFI or light obscuration method, containing no more than 6,000 particles of 10 μm and above per bottle, and no more than 600 particles of 25 μm and above per bottle; (iv) stable under shaking and / or repeated freezing and thawing; (v) the change in the percentage of light chain and heavy chain (LC+HC) peak area is less than 5%, or the change in the percentage of the main peak area is less than 5%, as measured by reduced CE-SDS or non-reduced CE-SDS method for size isomers, and / or the preparation has a purity greater than 90%; and (vi) The biological activity should be 70%-130% of the activity of the reference product.

36. A solid antibody preparation obtained by solidifying the liquid antibody preparation according to any one of claims 1 to 35, wherein the solidification is carried out by, for example, crystallization, spray drying or freeze drying, and the solid antibody preparation is, for example, in the form of a lyophilized powder injection.

37. A delivery device comprising the liquid antibody formulation of any one of claims 1-35 or the solid antibody formulation of claim 36.

38. A delivery device according to claim 37 which is a pre-filled syringe for intravenous, subcutaneous or intramuscular injection, or an infusion, such as for intravenous infusion.

39. Use of a liquid antibody formulation according to any one of claims 1 to 35 or a solid antibody formulation according to claim 36 for the preparation of a medicament or a delivery device for delivering an anti-CCR8 antibody or antigen-binding fragment to a subject.

40. Use of a liquid antibody formulation according to any one of claims 1-35 or a solid antibody formulation according to claim 36 for the preparation of a delivery device or a medicament for targeting a tumor infiltrating lymphocyte subpopulation, such as regulatory T cells (Tregs), in a subject.

41. The use according to claim 40, wherein the anti-CCR8 antibody or antigen-binding fragment inhibits Tregs migration, eliminates Tregs by antibody-dependent cellular cytotoxicity, or both.

42. Use of a liquid antibody formulation according to any one of claims 1 to 35 or a solid antibody formulation according to claim 36 for preparing a delivery device or medicament for treating cancer in a subject, for example, colorectal cancer, breast cancer, ovarian cancer, lung cancer (e.g., non-small cell lung cancer), melanoma, liver cancer, kidney cancer, bladder cancer, or pancreatic ductal adenocarcinoma.

Citation Information

Patent Citations

  • Novel Anti-CCR8 antibody

    CN113260381A

  • Anti-CCR8 antibodies and uses thereof

    CN114929278A

  • Anti-CCR8 antibody therapy: biomarkers and combination therapy

    CN116096750A

  • CCR8 antibodies for therapeutic applications

    US11427640B1

  • Novel Anti-CCR8 Antibody

    US20220064312A1

Cited By

  • Pharmaceutical formulations of anti-crr8 antibodies

    CN123057106A

  • Pharmaceutical formulation for Anti-CCR8 antibodies

    WO2025186043A1

  • Pharmaceutical composition comprising Anti-human CGRP antibody

    WO2026149405A1